

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
Our Ref.: H2216 EP(1S3)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/22805 A2

(51) International Patent Classification?: **C12N 15/00**

MA 02445 (US). ZHENG, Xin, Xiao [CN/US]; 59 Alton Place, Unit 6, Brookline, MA 02446 (US).

(21) International Application Number: **PCT/US01/28612**

(74) Agents: **FREEMAN, John, W. et al.**; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).

(22) International Filing Date:

14 September 2001 (14.09.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/232,251 14 September 2000 (14.09.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/232,251 (CON)
Filed on 14 September 2000 (14.09.2000)

Published:

— without international search report and to be republished upon receipt of that report

(71) Applicant (*for all designated States except US*): **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.** [US/US]; One Deaconess Road, Boston, MA 02115 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LI, Xian, Chang** [—/US]; 17 Hemlock Road, Newton, MA 02215 (US).
STROM, Terry [US/US]; 22 Kennard Road, Brookline,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/22805 A2

(54) Title: **MODULATION OF IL-2- AND IL-15-MEDIATED T CELL RESPONSES**

(57) Abstract: The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells *in vivo*. In one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that, when administered to a patient (or to a transplant *ex vivo*, reduce the number of antigen-reactive T cells. For example, the invention features compositions (e.g., pharmaceutically acceptable compositions) that include two or more agents, each of which promote T cell death. Alternatively, the composition can contain at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation. The agent that promotes T cell death can promote AICD (activation induced cell death), passive cell death, ADCC (antibody dependent cell-mediated cytotoxicity) or CDC (complement directed cytotoxicity).

MODULATION OF IL-2- AND IL-15-MEDIATED T CELL RESPONSES

This application claims the benefit of U.S.S.N. 60/232,251, filed September 14, 2000.

TECHNICAL FIELD

5 This invention relates to immunology, transplant rejection, and diseases associated with the immune system.

FEDERALLY SPONSORED RESEARCH

The work described herein was supported in part by a grant from the National Institutes of Health. The United States government may, therefore, have certain rights in
10 the invention.

BACKGROUND

Two of the interleukins, IL-2 and IL-15, are functionally redundant in stimulating T cell proliferation *in vitro*. However, their role in primary immune activation and immune homeostasis *in vivo* is much less clear. *In vivo*, IL-2 and IL-15 may have distinct functions
15 and regulate distinct aspects of T cell activation. For example, IL-2 may prime activated T cells for apoptosis (Lenardo, *Nature* 353:858-861, 1991), while IL-15 may support cell survival (Dooms *et al.*, *J. Immunol.* 161:2141-2150, 1998; Bulfone *et al.* *Nature Medicine* 3:1124-1128, 1997). IL-15 also appears to drive the proliferation of memory type CD8⁺ T cells *in vivo* while IL-2 limits their continued expansion (Ku *et al.*, *Science* 288:675-678,
20 2000). In addition, the phenotype of IL-2 deficient mice is lymphoproliferative and autoimmune (Horak *et al.*, *Immunol. Rev.* 148:35-44, 1995), whereas IL-15 deficient mice are somewhat lymphopenic and unable to mount a primary response to viral challenge (Kennedy *et al.*, *J. Exp. Med.* 191:771-780, 2000; Lodolce *et al.*, *Immunity* 9:669-676, 1998). The molecular basis for this striking dichotomy remains enigmatic.

25 The functional receptors for IL-2 and IL-15 consist of a private α chain, which defines the binding specificity for IL-2 or IL-15, and shared IL-2 receptor β and γ chains.

The γ chain is also a critical signaling component of the IL-4, IL-7, and IL-9 receptors (Sugamura *et al.*, *Ann. Rev. Immunol.* 14:179-205, 1996). In the lymphoid compartment, these receptor subunits can be expressed individually or in various combinations resulting in the formation of receptors with different affinities and/or with distinct signaling capabilities (Sugamura *et al.*, *supra*). For example, the β chain can associate with either the α chain or the γ chain to form dimeric structures, or with both the α and γ chains to form trimeric structures. Similarly, the γ chain can interact with the β chain and, through the β chain, with the α chain of either the IL-2 receptor or the IL-15 receptor. The IL-15 receptor α chain alone, in contrast to the IL-2 receptor α chain, can bind to IL-15 with a remarkably high affinity (Giri *et al.*, *EMBO J.* 14:3654-3663, 1995). However, similar to IL-2 receptor α chain, this interaction is not believed to trigger signaling events. Thus, trimerization of α , β , and γ chain subunits is essential for the functional integrity of high affinity receptors for both IL-2 and IL-15.

In vitro studies have shown that activated T cells can express both IL-2 receptor α chain and IL-15 receptor α chain (Chae *et al.*, *J. Immunol.* 157:2813-2819, 1996) and the β and γ chains are constitutively expressed by activated T cells (Ishii *et al.*, *Int. Immunol.* 6:1273-1277, 1994). Furthermore, both IL-2 and IL-15 are readily detected during immune activation *in vivo* (Li *et al.*, *J. Immunol.* 161:890-896, 1998). Thus, it is unclear how activated T cells distinguish between IL-2, IL-15, and other γ chain dependent cytokines *in vivo*.

SUMMARY

The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells *in vivo*. Surprisingly, these subunits direct activated T cell responses to IL-2 or IL-15 in a selective manner and, thereby, regulate the T cell response *in vivo*. In other words (and contrary to the conventional wisdom that IL-2 and IL-15 are redundant), IL-2 and IL-15 perform different roles in controlling T cell proliferation *in vivo*. In particular, IL-15 is critical for initiating T cell division, whereas IL-2 controls T cell expansion via down-regulation of γc expression. Accordingly, in one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of

suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that antagonizes an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that antagonizes an IL-2 molecule or an IL-2 receptor (IL-2R). In alternative embodiments, the compositions of the invention can include
5 (in place of, or in addition to, the agents described above), agents that inhibit the expression of the nucleic acids (*e.g.*, DNA or RNA) that encode an interleukin (*e.g.*, IL-2 or IL-15) or an interleukin receptor (*e.g.*, an IL-2 or an IL-15 receptor).

More generally, the invention features novel combinations of agents that, when administered to a patient, reduce the number of antigen-reactive T cells. For example, the
10 invention features compositions (*e.g.*, pharmaceutically acceptable compositions) that include two or more agents, each of which promote T cell death. Alternatively, the composition can contain at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation. The agent that promotes T cell death can promote AICD (activation induced cell death), passive cell death, ADCC (antibody dependent cell-mediated cytotoxicity) or CDC (complement directed cytotoxicity).
15

Agents that promote AICD include IL-2 and related molecules (*e.g.*, IL-2/Fc or other molecules that function as agonists of IL-2 or the IL-2 receptor (*e.g.*, an antibody that specifically binds to the IL-2 receptor and mimics the binding of the receptor's natural ligand)). Another agent that promotes AICD is the Fas Ligand (FasL). Agents
20 that promote passive cell death include agents that antagonize IL-15 (by targeting, *e.g.*, binding to, and thereby inhibiting the activity of, IL-15, an IL-15 receptor, or a component of the intracellular signaling pathway that is activated once a receptor is bound) or any other factor required for T cell survival (*e.g.*, IL-4, IL-7, OX-4 ligand, IFN- β , 4-1BB, or IGF-I). In alternative embodiments, the compositions of the invention can include (in
25 place of, or in addition to, one or more of the agents described above), agents that inhibit the expression of the nucleic acids (*e.g.*, DNA or RNA) that encode an interleukin (*e.g.*, IL-2 or IL-15) or an interleukin receptor (*e.g.*, an IL-2 or an IL-15 receptor).

One can promote ADCC or CDC by exposing a T cell to an agent that binds to the T cell surface and contains an Fc portion that activates ADCC or CDC. More specifically,
30 agents that promote ADCC or CDC include fusion proteins that contain an interleukin (*e.g.*,

IL-2 or a mutant IL-15) and an Fc region (*e.g.*, IL-2/Fc) as well as antibodies or other Fc-containing proteins that bind to an interleukin receptor (*e.g.*, an IL-2 or an IL-15 receptor).

As stated above, the compositions of the invention can include not only an agent that promotes T cell death, but also an agent that inhibits T cell proliferation. Agents that inhibit
5 T cell proliferation include rapamycin, mycophenolate mofetil (MMF), azathioprine, and any of the other agents known and used in the art to prevent cellular proliferation (including chemotherapeutic agents). The use of an agent that inhibits T cell proliferation is particularly useful in combination with agents that promote AICD and also stimulate T cell proliferation (such as IL-2/Fc). For example, the invention features a pharmaceutically acceptable
10 composition that includes IL-2/Fc (which, for example, promotes AICD and cellular lysis via ADCC or CDC), an IL-15 antagonist (which, for example, promotes passive cell death by antagonizing IL-15, a factor required for T cell survival), and rapamycin (which inhibits T cell proliferation). Compositions containing other combinations of agents are described below.

Notably, when two or more agents are employed, they need not be physically separate
15 from one another. While an agent can be a single entity that has primarily one functional activity (*e.g.*, an antibody that targets IL-2 or IL-15 by specifically binding IL-2 or IL-15), it can also be a single entity that has at least two functional activities (*e.g.*, IL-2/Fc, mIL-15/Fc, or an anti-IL-2 or anti-IL-15 antibody; in these molecules, the interleukin mediates
20 AICD and the Fc portion of the molecule mediates CDC and ADCC). Thus, a composition that includes (1) an agent that induces AICD, (2) an agent that induces CDC, and (3) an agent that inhibits cellular proliferation may include only two active ingredients (*e.g.*, (1) an IL-2/Fc molecule, which induces AICD and CDC, and (2) rapamycin, which inhibits cellular proliferation).

25 The compositions described herein are useful in treating patients who would benefit from immune suppression (*e.g.*, a patient who has received, or is scheduled to receive, a transplant; a patient who has an immune disease, particularly an autoimmune disease; a patient who has cancer (*e.g.*, a cancer of the immune system), or a patient suffering from graft versus host disease (GVHD)). GVHD is characterized by a response
30 of donor leukocytes against antigens in the recipient. This response is particularly

problematic in bone marrow transplants, but also occurs in whole organ transplants; donor leukocytes resident in transplanted organs are always co-transplanted.

Although the compositions of the invention can contain more than one agent, the methods of the invention are not limited to those in which the agents are administered

5 simultaneously. For example, a patient could receive a composition containing an IL-15 antagonist or an IL-15R antagonist before receiving a composition containing an IL-2 antagonist or an IL-2R antagonist. Similarly, a patient could receive a composition containing rapamycin before receiving a composition containing an IL-2 agonist.

Moreover, the compositions of the invention (applied simultaneously or sequentially) can
10 be used to treat an organ or cellular graft before it is implanted in a patient. The agents of the invention, and methods for their use, are described further below.

Many of the agents used in the context of the present invention have advantageous therapeutic characteristics. For example, agents that target an IL-15R can be fusion proteins that include a mutant IL-15 (mIL-15) polypeptide. These agents are unlikely to be
15 immunogenic because the mutant IL-15 portion of the fusion protein can differ from wild type IL-15 by only a few substituted residues. In addition, since mIL-15 polypeptides can bind the IL-15R α with high affinity, they can compete effectively with wild type IL-15 for the receptor. Further, agents of the invention can activate components of the host immune system, such as complement and phagocytes, which ultimately mediate elimination of (or
20 depletion of) cells bearing the receptor (e.g., an IL-2 receptor) to which the agent binds. For example, agents of the invention can mediate lysis or phagocytosis of targeted cells. As the alpha subunit of the IL-15 receptor (IL-15R α) is expressed by activated or malignant immune cells, but not by resting immune cells, agents of the invention can be used to specifically target those cells that have been activated (e.g., antigen-activated T cells) or that have become
25 malignant. Thus, although T cells represent a preferred target for the agents of the invention, the compositions of the invention can also be used to target other cells involved in the pathogenesis of immunological disorders, such as other cells of the immune system or hyperproliferating cells of tissues.

Unless otherwise defined, all technical and scientific terms used herein have the same
30 meaning as commonly understood by one of ordinary skill in the art to which this invention

belongs. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety.

Other features and advantages of the invention will be apparent from the drawings, the detailed description, and claims. Although materials and methods similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred materials and methods are described below.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a representation of a wild-type IL-15 nucleic acid sequence (SEQ ID NO:1) and the predicted amino acid sequence (SEQ ID NO:2).

Fig. 2 is a representation of a mutant IL-15 nucleic acid sequence (SEQ ID NO:3) and the predicted amino acid sequence (SEQ ID NO:4). The wild-type codon encoding glutamine at position 149, CAG, and the wild-type codon encoding glutamine at position 156, CAA, have both been changed to GAC, which encodes aspartate. (These positions (149 and 156) correspond to positions 101 and 108, respectively, in the mature IL-15 polypeptide, which lacks a 48-amino acid signal sequence).

Fig. 3A is a series of plots depicting expression of IL-2 receptor α , β and γ chains by dividing T cells in a host spleen 3 days after intravenous (i.v.) injection of CFSE-labeled cells. Representative data of six experiments are shown.

Fig. 3B is a series of plots depicting expression of IL-2 receptor α , β and γ chains by dividing T cells *in vitro*. CFSE-labeled cells lymphocytes were stimulated with anti-CD3 (2 μ g/ml) *in vitro* for three days. Cell division and the expression of IL-2 receptor subunits were analyzed by fluorescence-activated cell sorting (FACS).

Fig. 3C is a plot depicting expression of L-selectin by dividing T cells *in vivo*. Cells were harvested from lymph nodes of host mice three days after intravenous injection of CFSE-labeled cells and stained with PE-anti-CD62L mAb. The quadrant was set based on cells stained with isotype control mAb.

Fig. 3D is a series of plots depicting differential expression of IL-2 receptor α chain between *in vivo* dividing T cells. CFSE-labeled cells were stimulated *in vivo* for three days and cells in the second cell division were sorted. The sorted cells were re-stimulated

in vitro with anti-CD3 and anti-CD28 for three days. Cells division and expression of the IL-2 receptor α chain were analyzed by FACS.

Fig. 4A is a series of plots depicting expression of IL-15 receptor α chain by dividing T cells *in vivo* three days after intravenous injection of CFSE-labeled cells. Cells were stained with an IL-15-FLAG fusion protein, followed by staining with biotinylated anti-FLAG mAb and PE-streptavidin. Cell staining in the absence of IL-15-FLAG was included as a control.

Fig. 4B is a bar graph depicting the different response of *in vivo* dividing T cells to IL-2 and IL-15 *in vitro*. CFSE-labeled lymphocytes were stimulated *in vivo* for three days and cell division was analyzed by examining the CFSE profile. T cells in the second cell division were sorted and cells (1×10^4) were cultured *in vitro* with IL-2 or IL-15 for two days. Cellular proliferation was determined by ^3H -TdR uptake. The results are presented as the mean CPM \pm SD of triplicate assays.

Fig. 4C is a pair of graphs depicting the effect of anti-CD25 treatment on T cell division *in vivo*. Host mice were given anti-CD25 mAb intraperitoneally (i.p.) at 1 mg/day for three days immediately before intravenous injection of CFSE-labeled cells. Mice treated with isotype control mAb (rat IgG1) were included as a control.

Fig. 5A is a series of plots depicting intracellular IL-2 staining of *in vivo* dividing T cells. CFSE-labeled cells were stimulated *in vivo* for three days. Cells harvested from the host spleen were stimulated *in vitro* with PMA and ionomycin for four hours in the presence of GolgiStopTM. Cells were then fixed, permeablized, and stained for IL-2 production. Cells stained with isotype control mAb were included as a control.

Fig. 5B is a pair of graphs depicting expression of γc by CD4^+ T cells from IL-2 deficient mice. Spleen cells from IL-2 deficient mice and wild type control mice were stained with PE-anti-mouse CD4 mAb and FITC-anti-mouse IL-2 receptor γc mAb. The expression of γc by CD4^+ T cells was analyzed by FACS.

Fig. 5C is a series of plots depicting the effect of anti-CD25 treatment on γc expression by dividing T cells *in vivo*. Host mice were given anti-CD25 mAb at 1 mg/day (i.p.) for three days immediately before intravenous injection of CFSE-labeled cells. Expression of IL-2 receptor β and γ chains on dividing T cells *in vivo* was determined on

day three (*i.e.*, three days after injection of CFSE-labeled cells). Mice treated with an isotype control mAb (rat IgG1) were included as a control.

Fig. 5D is a series of plots depicting apoptotic cell death of *in vivo* dividing T cells. CFSE-labeled cells were stimulated *in vivo* for three days. Cells were harvested from the host spleen and stained with PE-annexin V. Cell division and apoptotic cell death were analyzed by FACS.

Fig. 5E is a series of plots depicting intracellular Bcl-2 expression by dividing T cells *in vivo*. CFSE-labeled cells were stimulated *in vivo* for three days. Cells harvested from the host spleen were stained with PE-anti-mouse Bcl-2 mAb or an isotype control mAb. Cell division and expression of Bcl-2 were analyzed by FACS.

Fig. 6 is a bar graph depicting the results of an experiment in which cell death (assessed by release of the isotope ^{51}Cr from CTLL-2 cells; see the x axis) was assessed following treatment with various agents. NP40 is a detergent; IL-2/Fc is a fusion protein that contains IL-2 and the Fc region of an IgG molecule (this molecule is lytic); C' is rat complement; IL-2/Fc-/- is a non-lytic IL-2-containing fusion protein; and mIg is a murine immunoglobulin. This study supports the conclusion that cytolytic IL-2/Fc lyses IL-2R-bearing CTLL-2 cells, but non-lytic IL-2/Fc does not.

Fig. 7 is a series of histograms. The fluorescence intensity of FcRI on CHO (Chinese hamster ovary) cells was measured after the cells were exposed to phosphate buffered saline (PBS; upper left), a murine immunoglobulin (mIgG2a; upper right), a non-lytic IL-2/Fc molecule (IL-2/Fc-/-; lower left), and a lytic IL-2 containing fusion protein (IL-2/Fc; lower right). In each histogram, cell number is plotted against the fluorescence intensity of FcRI/CHO. This study supports the conclusion that cytolytic IL-2/Fc binds to FcRI, but non-lytic IL-2/Fc does not.

Fig. 8 is a series of eight plots depicting the proliferative response of CD4^+ (left-hand side) and CD8^+ (right-hand side) T cells *in vivo*. The cells were labeled with CFSE and stimulated *in vivo* for three days with a lytic molecule (IL-2/Fc), a cell proliferation agent (rapamycin (Rap)), or the two agents combined. As a negative control, one group of animals was not treated. IL-2/Fc was analyzed by their CFSE profile. This study supports the conclusion that rapamycin inhibits IL-2 proliferative signaling.

Fig. 9 is a series of four plots obtained from an experiment in which CFSE-labeled lymphocytes were stimulated *in vivo* for three days. The expression of an IL-2R α chain on dividing T cells was assessed by FACS in animals that received no treatment (upper left), rapamycin alone (Rap; upper right), IL-2/Fc alone (lower left), or a combination of rapamycin and IL-2/Fc (Rap + IL-2/Fc; lower right). This study supports the conclusion that treatment with rapamycin and IL-2/Fc promotes expression of the α subunit of the IL-2R during early T cell proliferation *in vivo*.

Fig. 10 is a pair of plots obtained when CFSE-labeled lymphocytes were stimulated *in vivo* for three days and analyzed by FACS. The expression of Annexin V on dividing T cells (CD4⁺) was assessed in animals that received no treatment (left hand panel) or rapamycin and IL-2/Fc (Rap + IL-2/Fc; right hand panel). This study supports the conclusion that rapamycin and IL-2/Fc treatment promotes apoptosis of CD4⁺ cells during early T cell proliferation *in vivo*.

Fig. 11 is a Table showing the results of experiments that examined islet allograft survival in autoimmune non-obese diabetic (NOD) mice. The grafts were assessed in terms of primary allograft function (the percentages shown in this column represent the percentage of mice in which the allograft functioned (function was assessed by monitoring blood glucose levels)) and the mean survival time (MST) of the functioning grafts. n = the number of animals tested. The treatments are indicated under the heading "Treatment" (*see also* the legend that accompanies the Table and the description below). The results presented here support the conclusion that treatment with a combination of rapamycin, IL-2/Fc and mIL-15/Fc results in long-term survival of islet allografts.

Fig. 12 is a Table showing the results of experiments that examined the survival of skin allografts in NOD mice. The grafts were assessed in terms of the mean survival time (MST) of functioning grafts. n = the number of animals tested. The treatments are indicated under the heading "Treatment" (*see also* the legend that accompanies the Table and the description below). The results presented here support the conclusion that treatment with a combination of rapamycin, IL-2/Fc and mIL-15/Fc results in long-term survival of skin allografts.

Fig. 13 is a line graph that plots the % of animals that remained diabetes free over time following treatment with a lytic IL-2/Fc molecule, a murine immunoglobulin (mIg), and a non-lytic IL-2/Fc molecule. Cytolytic IL-2/Fc blocked autoimmunity, but lytic IL-2/Fc did not.

5

DETAILED DESCRIPTION

An effective immune response begins when an antigen or mitogen triggers the activation of T cells. In the process of T cell activation, numerous cellular changes occur, which include the expression of cytokines and cytokine receptors. One of the cytokines involved in the immune response is interleukin-15 (IL-15), which is a T cell growth factor that stimulates the proliferation and differentiation of B cells, T cells, natural killer (NK) cells, and lymphocyte-activated killer (LAK) cells *in vitro*. *In vivo*, the proliferation of these cell types enhances the immune response. Another cytokine involved in the immune response, and described herein, is IL-2.

The compositions of the present invention include agents that target IL-15, or its receptor, and IL-2, or its receptor, and methods in which those compositions are used to suppress an immune response (*e.g.*, a humoral or cellular immune response). Patients benefit from suppression of the immune response in a number of circumstances, for example, in the event of organ transplantation or immune disease, particularly autoimmune disease, or Graft Versus Host Disease. In other circumstances, for example when select immune cells have become malignant or autoaggressive, it is beneficial to actively destroy them.

The present invention is based on the discovery of novel ways to inhibit the immune response. Inhibition can be achieved by administering of a combination of agents, one of which targets IL-15 or an IL-15R and one of which targets IL-2 or an IL-2R (modes of administration, including *ex vivo* treatment of grafts, are known in the art and described further below). More generally, one can reduce the number of antigen-reactive T cells by activating signaling pathways that lead to the death of activated T cells (by, *e.g.*, AICD); depriving cells of factors that are required for their survival (cells that die following such deprivation are said to die by passive cell death); or targeting activated

cells for lysis by components of the immune system (cells that die in this way are said to die by ADCC or CDC). Accordingly, the compositions of the invention include agents that achieve one or more of these ends (*i.e.*, that promote T cell death via a recognized cell death pathway (*e.g.*, AICD, passive cell death, ADCC, or CDC)). In addition to
5 containing one or more agents that promote T cell death, the compositions of the invention can include one or more agents that inhibit T cell proliferation (as occurs, *e.g.*, in response to an antigen). For example, the invention features a composition (*e.g.*, a pharmaceutically acceptable composition or one formulated for application to an organ or cell culture) that includes IL-2/Fc (which, for example, promotes AICD and cellular lysis
10 via ADCC or CDC), mIL-15/Fc (which antagonizes IL-15 (and thereby promotes passive cell death) and promotes cellular lysis via ACDD or CDC), and rapamycin (which inhibits T cell proliferation).

The term "agent" is meant to encompass essentially any type of molecule that can be used as a therapeutic agent. Proteins, such as antibodies, fusion proteins, and
15 soluble ligands, any of which may either be identical to a wild-type protein or contain a mutation (*i.e.*, a deletion, addition, or substitution of one or more amino acid residues), and the nucleic acid molecules that encode them (or that are "antisense" to them; *e.g.*, an oligonucleotide that is antisense to the nucleic acids that encode IL-2, IL-15, or a component (*e.g.*, a subunit) of their receptors), are all "agents." The agents of the
20 invention can either be administered systemically, locally, or by way of cell-based therapies (*i.e.*, an agent of the invention can be administered to a patient by administering a cell that expresses that agent to the patient). The cell can be a cell administered to the patient solely for the purpose of expressing the therapeutic agent. The cell can also be a cell of a cellular, tissue, or organ transplant. For example, transplanted cells (*e.g.*, islet
25 cells) or cells within tissues or organs (*e.g.*, cells within a patch of skin or a liver, kidney, or heart) can be treated with an agent or transduced with a nucleic acid molecule that encodes an agent *ex vivo* (*e.g.*, prior to transplantation). In this way, the transplanted cell produces its own immunosuppressive agents. For example, a cell with a desirable phenotype (*e.g.*, an insulin producing cell) can be modified to include a gene producing
30 one or more of the immunosuppressive factors of the invention. The transplanted cell,

tissue, or organ can be treated either prior to or subsequent to transplantation. Methods of administering agents to patients (or to cells or organs in culture) are known and routinely used by those of ordinary skill in the art and are discussed further below.

5 Agents that Target IL-15 or an IL-15R

The compositions of the invention can include one or more agents that target IL-15 or an IL-15 receptor. As noted above, a single agent can have multiple functional domains. Agents that target IL-15 or an IL-15R include agents that bind to (or otherwise interact with) IL-15, an IL-15R, or the nucleic acids that encode them as well as agents
10 that bind to and subsequently destroy IL-15R-bearing cells, such as activated T cells. Thus, agents useful in achieving immune suppression can contain two functional moieties: a targeting moiety that targets the agent to an IL-15R-bearing cell and a target-cell depleting (*e.g.*, lytic) moiety that leads to the elimination of the IL-15R-bearing cell. In one embodiment, the targeting moiety binds an IL-15R without effectively transducing a
15 signal through that receptor. For example, the targeting moiety can include a mutant IL-15 polypeptide, and the target-cell depleting moiety can include the Fc region of an immunoglobulin molecule. The Fc region can be derived from an IgG, such as human IgG1, IgG2, IgG3, IgG4, or analogous mammalian IgGs or from an IgM, such as human IgM or analogous mammalian IgMs. In a preferred embodiment, the Fc region includes
20 the hinge, CH2 and CH3 domains of human IgG1 or murine IgG2a. Although the invention is not limited to agents that work by any particular mechanism, it is believed that the Fc region mediates complement and phagocyte-driven elimination of IL-15R-bearing cells.

Mutant IL-15 polypeptides that bind the IL-15 receptor complex with an affinity similar to wild-type IL-15, but fail to fully activate signal transduction, have been produced. These mutant polypeptides compete effectively with wild-type IL-15 polypeptides and can inhibit one or more of the events that normally occur in response to IL-15 signaling, such as cellular proliferation. The "wild-type IL-15 polypeptide" referred to herein is a polypeptide that is identical to a naturally occurring IL-15 (e.g., a wild-type IL-15 polypeptide is shown in Fig. 1). In contrast, a "mutant IL-15 polypeptide" is a polypeptide that has at least one mutation relative to wild-type IL-15 and that inhibits at least one of the *in vivo* or *in vitro* activities that are usually promoted by wild-type IL-15.

A mutant IL-15 polypeptide that can be used according to the present invention will generally block at least 40%, more preferably at least 70%, and most preferably at least 90% of one or more of the activities of the wild-type IL-15 molecule. The ability of a mutant IL-15 polypeptide to block wild-type IL-15 activity can be assessed by numerous assays, including the BAF-BO3 cell proliferation assay described herein (in which the cells were transfected with a construct encoding IL-2R β). Further, mutant polypeptides of the invention can be defined according to the particular percent identity they exhibit with wild-type IL-15. When examining the percent identity between two polypeptides, the length of the sequences compared will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably at least 35 amino acids. The term "identity," as used in reference to polypeptide or DNA sequences, refers to the identity between subunits (amino acid residues of proteins or nucleotides of DNA molecules) within the two polypeptide or DNA sequences being compared. When a subunit position in both of the molecules is occupied by the same monomeric subunit (*i.e.*, the same amino acid residue or nucleotide), then the molecules are identical at that position. The similarity between two amino acid sequences or two nucleotide sequences is a direct function of the number of identical positions. Thus, a polypeptide that is 50% identical to a reference polypeptide that is 100 amino acids long can be a 50 amino acid polypeptide that is completely identical to a 50 amino acid long portion of the reference polypeptide. It might also be a 100 amino acid long polypeptide that is 50% identical to the reference polypeptide over its entire length. Of course, many

other polypeptides will meet the same criteria. Identity is typically and most conveniently measured using sequence analysis software, such as the Sequence Analysis Software Package of the Genetics Computer Group at the University of Wisconsin Biotechnology Center (1710 University Avenue, Madison, WI 53705), with the default parameters thereof.

A mutant IL-15 polypeptide of the invention can be at least 65%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% (*e.g.*, 96%, 97%, 98% or 99%) identical to wild-type IL-15. The mutation can consist of a change in the number or content of amino acid residues. For example, the mutant IL-15 can have a greater or a lesser number of amino acid residues than wild-type IL-15. Alternatively, or in addition, the mutant polypeptide can contain a substitution of one or more amino acid residues that are present in the wild-type IL-15. The mutant IL-15 polypeptide can differ from wild-type IL-15 by the addition, deletion, or substitution of a single amino acid residue, for example, an addition, deletion or substitution of the residue at position 156. Similarly, the mutant polypeptide can differ from wild-type by an addition, deletion, or substitution of two amino acid residues, for example, the residues at positions 156 and 149. For example, the mutant IL-15 polypeptide can differ from wild-type IL-15 by the substitution of aspartate for glutamine at residues 156 and 149 (as shown in Fig. 2). Mutant polypeptides useful as targeting agents, like wild-type IL-15, recognize and bind a component of the IL-15R. In one embodiment, the mutation of IL-15 is in the carboxy-terminal domain of the cytokine, which is believed to bind IL-2R γ (the IL-2 receptor subunit). Alternatively, or in addition, mutant IL-15 polypeptides can include one or more mutations within IL-2R β (the IL-2 receptor β subunit) binding domain.

In the event a mutant IL-15 polypeptide contains a substitution of one amino acid residue for another, the substitution can be, but is not necessarily, a conservative substitution, which includes a substitution within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

Instead of using, or in addition to using, an IL-15 targeting polypeptide (*e.g.*, a mutant IL-15 polypeptide), the therapeutic agent can be an antibody. For example, IL-15

can be targeted (*i.e.*, specifically bound) with an antibody. Similarly, the IL-15R can be targeted with antibodies that bind a component of the IL-15R (*e.g.*, the IL-15R α subunit). The methods by which antibodies, including humanized antibodies, can be generated against a component of the IL-15R are well known in the art. The antibodies preferably
5 should be able to activate complement and phagocytosis, for example, human IgG3 and IgG1 (preferably the latter) subclasses, or murine IgG2a subclass.

The methods of the invention can also be carried out with compositions that contain: (a) two or more agents, each of which promote T cell death or (b) at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation.
10 The agent that promotes T cell death can do so by promoting passive cell death, which occurs when a T cell is deprived of a factor required for its survival. IL-15 is one such agent (others are described below). Thus, agents that interfere with the ability of IL-15 to serve as a survival factor (*e.g.*, an antibody that specifically binds to IL-15 or the IL-15 receptor) can be included in the compositions of the invention (*e.g.*, a composition can
15 include an agent that promotes AICD, an agent that promotes passive cell death (*e.g.*, an anti-IL-15 antibody), and, optionally, an agent that inhibits T cell proliferation.

As described above, agents useful in achieving immune suppression can contain two functional moieties: a targeting moiety that targets the agent to an IL-15R-bearing cell (such as the mutant IL-15 molecule just described) and a target-cell depleting
20 moiety that, for example, lyses or otherwise leads to the elimination of, the IL-15R-bearing cell. Thus, the agent can be a chimeric polypeptide that includes a mutant IL-15 polypeptide and a heterologous polypeptide such as the Fc region of the IgG and IgM subclasses of antibodies. The Fc region may include a mutation that inhibits complement fixation and Fc receptor binding, or it may be target-cell depleting (*i.e.*, able to destroy
25 cells by binding complement or by another mechanism, such as antibody-dependent complement lysis).

The Fc region can be isolated from a naturally occurring source, recombinantly produced, or synthesized (just as any polypeptide featured in the present invention can be). For example, an Fc region that is homologous to the IgG C-terminal domain can be
30 produced by digestion of IgG with papain. IgG Fc has a molecular weight of

approximately 50 kDa. The polypeptides of the invention can include the entire Fc region, or a smaller portion that retains the ability to lyse cells. In addition, full-length or fragmented Fc regions can be variants of the wild-type molecule. That is, they can contain mutations that may or may not affect the function of the polypeptide.

5 Reference is made herein to agents that "target" an interleukin or an interleukin receptor. Targeting occurs when an agent directly or indirectly binds to, or otherwise interacts with, an interleukin or an interleukin receptor in a way that affects the activity of the interleukin or the interleukin receptor. Activity can be assessed by those of ordinary skill in the art and with routine laboratory methods. For example, one can assess the
10 strength of signal transduction or another downstream biological event that occurs, or would normally occur, following receptor binding. The activity generated by an agent that targets an interleukin or an interleukin receptor can be, but is not necessarily, different from the activity generated when a naturally occurring interleukin binds a naturally occurring interleukin receptor. For example, an agent that targets an IL-2 receptor falls
15 within the scope of the invention even if that agent generates substantially the same activity that would occur had the receptor been bound by naturally occurring IL-2. When an agent generates activity that is substantially the same as, or greater than, the activity generated by a naturally occurring ligand, the agent can be described as a receptor agonist (the agent and the natural ligand being examined under the same conditions). When an
20 agent generates activity that is less than the activity generated by a naturally occurring ligand, the agent can be described as an antagonist of the receptor (if the agent's primary interaction is with the receptor; *e.g.*, mIL-15) or of the interleukin (if the agent's primary interaction is with the interleukin; *e.g.*, an anti-IL-15 antibody). Here again, levels of activity are assessed by testing the agent and the naturally occurring receptor (or ligand)
25 under the same conditions.

 The Fc region that can be part of the agents of the invention can be "target-cell depleting" or "non-target-cell depleting." A non-target-cell depleting Fc region typically lacks a high affinity Fc receptor binding site and a C'1q binding site. The high affinity Fc receptor binding site of murine IgG Fc includes the Leu residue at position 235 of IgG Fc.
30 Thus, the murine Fc receptor binding site can be destroyed by mutating or deleting Leu

235. For example, substitution of Glu for Leu 235 inhibits the ability of the Fc region to bind the high affinity Fc receptor. The murine C'1q binding site can be functionally destroyed by mutating or deleting the Glu 318, Lys 320, and Lys 322 residues of IgG. For example, substitution of Ala residues for Glu 318, Lys 320, and Lys 322 renders IgG1 Fc
5 unable to direct antibody-dependent complement lysis. In contrast, a target-cell depleting IgG Fc region has a high affinity Fc receptor binding site and a C'1q binding site. The high affinity Fc receptor binding site includes the Leu residue at position 235 of IgG Fc, and the C'1q binding site includes the Glu 318, Lys 320, and Lys 322 residues of IgG1. Target-cell depleting IgG Fc has wild-type residues or conservative amino acid
10 substitutions at these sites. Target-cell depleting IgG Fc can target cells for antibody dependent cellular cytotoxicity or complement directed cytotoxicity (CDC). Appropriate mutations for human IgG are also known (*see, e.g., Morrison et al., The Immunologist* 2:119-124, 1994; and Brekke et al., *The Immunologist* 2:125, 1994).

Agents that target the IL-15R can mutant IL-15 polypeptides, optionally fused
15 to an antigenic tag (*e.g., a FLAG sequence*). FLAG sequences are recognized by biotinylated, highly specific, anti-FLAG antibodies, as described herein (see also Blonar et al., *Science* 256:1014, 1992; LeClair et al., *Proc. Natl. Acad. Sci. USA* 89:8145, 1992).

In addition, soluble IL-15R α chain can be used as antagonist. While the IL-15 receptor complex consists of $\alpha \beta \gamma$ subunits, the α chain alone displays a high affinity for
20 IL-15. Thus, soluble IL-15R α chain will bind IL-15 and prevent IL-15 from binding to a cell surface-bound IL-15R complex. Thus, a soluble IL-15R α chain can act as a receptor-specific antagonist.

Construction of soluble IL-15R α chain involves cloning the extracellular fragment of the IL-15R α chain from receptor-positive cells, such as activated T cells or receptor
25 expressing cell lines, and, optionally, fusing it to a molecular tag sequence. The tag sequence can be, for example, FLAG, GST, or Histidine. This genetic construct in an expression vector can be transfected into expressing cell lines. The tagged soluble IL-15R α chain produced by expressing cell lines will be purified using mAbs specific for the Tag sequence. Furthermore, an IL-15R extracellular domain can be linked (*e.g., fused by way*
30 of a peptide bond) to an immunoglobulin Fc domain (*e.g. hinge, CH2 and CH3 domains*

of Immunoglobulin G), preferably of an IgG or IgM subtype. Such a fusion protein could be expressed in a suitable cell type, many of which are known to those of ordinary skill in the art.

5 Agents that Target IL-2 or an IL-2 Receptor

To inhibit an immune response, the agents that target IL-15R-bearing cells, described above, can be administered with an agent that targets IL-2 or an IL-2R. An agent that is administered "with" another may be, but is not necessarily, administered at the same time or in the same manner (while this comment is stated in the context of a discussion of IL-2-related agents, it is applicable for any of the agents or molecules combined in the compositions of the invention). For example, an agent that targets an IL-15R may be administered before or after an agent that targets an IL-2R. Similarly, an agent that targets IL-15 or an IL15R can be administered *ex vivo* (to treat, for example, a cell, tissue, or organ that is slated for transplantation) while an agent that targets IL-2 or an IL-2R can be administered systemically (*e.g.*, intravenously) to a patient (*e.g.* a patient who has received a transplant that was treated *ex vivo* with an agent that targets IL-15). Similarly, one can administer an agent that promotes AICD at a different time or in a different manner than an agent that inhibits cellular proliferation. Thus, in the methods of the invention, any of the agents or types of molecules that are combined in the compositions of the invention can be administered separately.

To inhibit an IL-2R, one can administer any agent that binds to and antagonizes IL-2 or an IL-2R. Agents that target IL-2 or an IL-2R include agents that bind to IL-2 or an IL-2R as well as agents that bind to and subsequently destroy IL-2R-bearing cells, such as activated T cells. As described above in the context of IL-15 targeting, agents useful in achieving immune suppression can contain a moiety that targets the agent to an IL-2R-bearing cell and a target-cell depleting (*e.g.*, lytic) moiety that leads to the elimination of the IL-2R-bearing cell. For example, the targeting moiety can bind an IL-2R without effectively transducing a signal through that receptor. In the event an Fc region is included, that region can be derived from the same immunoglobulin molecules described above.

Targeting agents, such as an IL-2/Fc agent (*e.g.*, see Zheng *et al.*, *J. Immunol.* 163:4041-4048, 1999) can be administered with an agent that prevents IL-2-mediated IL-2R signaling, such as rapamycin. Agents that inhibit cellular proliferation are well known to those of ordinary skill in the art (and are discussed further below).

5 Instead of using, or in addition to using, an IL-2R targeting polypeptide (*e.g.*, an IL-2 polypeptide), the therapeutic agent used in combination with an IL-15 antagonist can be an anti-IL-2 or an anti-IL-2R antibody (*e.g.*, a humanized antibody) that antagonizes IL-2 or the IL-2R, respectively.

As explained above, the methods of the invention (*e.g.*, methods of inhibiting an immune response (*e.g.*, a cellular immune response), methods of inhibiting transplant rejection, and methods of treating cancer) can also be carried out with compositions (*e.g.*, pharmaceutically acceptable compositions) that contain: (a) two or more agents, each of which promote T cell death or (b) at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation. The agent that promotes T cell death can do so
15 by promoting AICD (activation induced cell death), and such agents include IL-2 and molecules that function as IL-2 agonists. For example, IL-2/Fc, mutants of IL-2 that retain the ability to bind and transduce a signal through the IL-2 receptor, and antibodies that specifically bind and agonize the IL-2 receptor (*e.g.*, an antibody that specifically binds the α subunit of the IL-2 receptor) can be included in the compositions of the
20 invention. Other agents that promote AICD include Fas Ligand (FasL), which stimulates T cell death by activating the Fas signal transduction cascade on activated T cells, and biologically active mutants thereof.

Agents that Promote Passive Cell Death

25 Passive T cell death occurs when a T cell is deprived of an agent that is required for its survival. In addition to IL-15, factors including IL-4, IL-7, OX-40 ligand, IFN β , 4-1BB and IGF-I are essential (*i.e.*, T cells die in the absence of each of these factors; *see, e.g.*, Tu *et al.*, *J. Immunol.* 165:1331-1336, 2000; Tsuda *et al.*, *J. Immunol. Meth.* 236:37-51, 2000; Bertolino *et al.*, *Int. Immunol.* 11:1225-1238, 1999; Takahashi *et al.*,
30 *J. Immunol.* 162:5037-5040, 1999; Pilling *et al.*, *Eur. J. Immunol.* 29:1041-1050, 1999;

Chu *et al.*, *J. Immunol.* 162:1896-1903, 1999; and Weinberg *et al.*, *Semin. Immunol.* 10:471-480, 1998). One can deprive T cells of one or more of these factors (IL-15, IL-4, IL-7, *etc.*) by, for example, exposing the cells, *in vivo* or in culture, to agents that selectively bind to one or more of the factors or otherwise prevent them from interacting with the T cell as they normally would (the result of the deprivation being passive cell death).

Agents that Promote ADCC or CDC

ADCC and CDC can be provoked by agents that bind to the T cell surface and that contain an Fc portion of an immunoglobulin molecule that activates ADCC or CDC. Examples of such agents include antibodies that bind to cell surface structures that are expressed on activated immune cells (*e.g.*, cell surface receptors such as CD154, the IL-2 receptor, and the IL-15 receptor). In addition, one can use a ligand/Fc chimeric fusion protein, which binds to receptor proteins on the surface of activated cells (*e.g.*, an IL-2/Fc or a mIL-15/Fc). Given these examples, other suitable agents will be apparent to those of ordinary skill in the art.

Agents that Inhibit Cellular Proliferation

Agents that inhibit cellular proliferation include rapamycin (Sirolimus), mycophenolate mofetil (MMF), azathioprine, and any other of the agents that are known to be useful for the treatment of hyperproliferative disorders (such as cancer). Well-characterized chemotherapeutics include agents that inhibit nucleic acid metabolism (such as purine and pyrimidine biosynthesis inhibitors, RNA synthesis inhibitors, and DNA binding, DNA modifying, or intercalating agents). These agents are especially useful when the composition used to, for example, inhibit an immune response, also contains an agent such as IL-2/Fc, which not only promotes AICD but also stimulates T cell proliferation.

Agents that inhibit cellular proliferation also include folic acid antimetabolites such as methotrexate (MTX) and pyrimethamine; purine antimetabolites (such as 6-mercaptopurine (6-MP) and azathioprine) and pyrimidine antagonists such as cytarabine

(ara-C), 5-azacytidine, and 5-fluorouracil (these categories were mentioned above); alkylating and other DNA-linking agents (e.g., cyclophosphamide (CPA); mitomycin C, and Doxorubicin (Adriamycin)); vinca alkaloids (e.g., vincristine); and calcineurin inhibitors (e.g., Cyclosporin A, FK506, and Brequinar).

5 Other agents that can be used to inhibit cellular proliferation include agents that interfere directly with proteins involved in cell cycle regulation (such as anti-CDKs (Cell Division Kinase) or anti-cyclins) or proteins that affect cell proliferation check points (all proliferating cells have check points at different stages of the cell cycle that prevent them from entering the next stage of the cell division cycle (CDC) before they have concluded
10 the previous step). Pathways that feed into check point controls include DNA-, RNA- and protein-synthesis inhibitors (e.g., S6 kinase and PI-3-kinase inhibitors). Cytokinesis inhibitors can also be used.

Procedures for Screening Agents that Inhibit the Immune Response

15 In addition to testing a candidate agent (e.g., a mutant IL-15 or IL-2 polypeptide) in the *in vitro* assays described in the examples below, one can use any of the following *in vivo* assays to test which particular combinations of the agents described herein most effectively bring about immune suppression. For example, one can test one or more of the agents that target the IL-15R in combination with one or more of the agents
20 that antagonize IL-2 or its receptor. These *in vivo* assays represent only some of the routine ways in which one of ordinary skill in the art could further test the efficacy of agents of the invention. They were selected for inclusion here because of their relevance to the variety of clinical conditions amenable to treatment with agents that target IL-2, IL-15, and their receptors. For example, the assays are relevant to organ transplantation,
25 immune disease, particularly autoimmune disease, graft versus host disease and cancers of the immune system (e.g. cancers that arise when T cells become malignant).

Transplantation Paradigms

To determine whether a combination of agents of the invention achieves immune suppression, the combination can be administered (either directly, by gene-based therapy, or by cell-based therapy) in the context of well-established transplantation paradigms.

Agents of the invention, nucleic acid molecules encoding them (or that hybridize with and thereby inhibit them), can be systemically or locally administered by standard means to any conventional laboratory animal, such as a rat, mouse, rabbit, guinea pig, or dog, before an allogeneic or xenogeneic skin graft, organ transplant, or cell implantation is performed on the animal. Strains of mice such as C57B1-10, B10.BR, and B10.AKM (Jackson Laboratory, Bar Harbor, ME), which have the same genetic background but are mismatched for the H-2 locus, are well suited for assessing various organ grafts.

Heart Transplantation

A method for performing cardiac grafts by anastomosis of the donor heart to the great vessels in the abdomen of the host was first published by Ono *et al.* (*J. Thorac. Cardiovasc. Surg.* 57:225, 1969; see also Corry *et al.*, *Transplantation* 16:343, 1973). By way of this surgical procedure, the aorta of a donor heart is anastomosed to the abdominal aorta of the host, and the pulmonary artery of the donor heart is anastomosed to the adjacent vena cava using standard microvascular techniques. Once the heart is grafted in place and warmed to 37°C with Ringer's lactate solution, normal sinus rhythm will resume. Function of the transplanted heart can be assessed frequently by palpation of ventricular contractions through the abdominal wall. Rejection is defined as the cessation of myocardial contractions. Agents of the invention (*e.g.*, a combination of mutant IL-15/Fc and an antibody that binds to and inhibits IL-2 or IL-2R, or a combination of a mutant IL-15/FC, IL-2/Fc, and rapamycin) would be considered effective in reducing organ rejection if hosts that received these agents experienced a longer period of engraftment of the donor heart than did untreated hosts.

Skin Grafting

The effectiveness of various combinations of the agents of the invention can also be assessed following a skin graft. To perform skin grafts on a rodent, a donor animal is anesthetized and the full thickness skin is removed from a part of the tail. The recipient animal is also anesthetized, and a graft bed is prepared by removing a patch of skin from the shaved flank. Generally, the patch is approximately 0.5 x 0.5 cm. The skin from the donor is shaped to fit the graft bed, positioned, covered with gauze, and bandaged. The grafts can be inspected daily beginning on the sixth post-operative day, and are considered rejected when more than half of the transplanted epithelium appears to be non-viable. Agents of the invention (e.g., a combination of mutant IL-15/Fc and an antibody that binds to and inhibits IL-2 or IL-2R, or a combination of a mutant IL-15/Fc, IL-2/Fc, and rapamycin) would be considered effective in reducing skin graft rejection if hosts that received these agents experienced a longer period of engraftment of the donor skin than did untreated hosts.

A typical example of a skin grafting experiment, the results of which demonstrate the usefulness of a composition containing IL-2/Fc, mIL-15/Fc and rapamycin, is described in the Examples (below) and summarized in Fig. 12.

Islet Allograft Model

DBA/2J islet cell allografts can be transplanted into rodents, such as 6-8 week-old B6 AF1 mice rendered diabetic by a single intraperitoneal injection of streptozotocin (225 mg/kg; Sigma Chemical Co., St. Louis, MO). As a control, syngeneic islet cell grafts can be transplanted into diabetic mice. Islet cell transplantation can be performed by following published protocols (for example, see Gotoh *et al.*, *Transplantation* 42:387, 1986). Briefly, donor pancreata are perfused *in situ* with type IV collagenase (2 mg/ml; Worthington Biochemical Corp., Freehold, NJ). After a 40-minute digestion period at 37°C, the islets are isolated on a discontinuous Ficoll gradient. Subsequently, 300-400 islets are transplanted under the renal capsule of each recipient. Allograft function can be followed by serial blood glucose measurements (Accu-Check III™; Boehringer, Mannheim, Germany). Primary graft function is defined as a blood

glucose level under 11.1 mmol/l on day 3 post-transplantation, and graft rejection is defined as a rise in blood glucose exceeding 16.5 mmol/l (on each of at least 2 successive days) following a period of primary graft function.

5 Models of Autoimmune Disease

Models of autoimmune disease provide another means to assess combinations of the agents of the invention *in vivo*. These models are well known to those of ordinary skill in the art and can be used to determine whether a given combination of agents, which includes, for example, an agent that targets an IL-15R, would be therapeutically useful in
10 treating a specific autoimmune disease when delivered either directly, via genetic therapy, or via cell-based therapies.

Autoimmune diseases that have been modeled in animals include rheumatic diseases, such as rheumatoid arthritis and systemic lupus erythematosus (SLE), type I diabetes, and autoimmune diseases of the thyroid, gut, and central nervous system. For
15 example, animal models of SLE include MRL mice, BXSB mice, and NZB mice and their F₁ hybrids. These animals can be crossed in order to study particular aspects of the rheumatic disease process; progeny of the NZB strain develop severe lupus glomerulonephritis when crossed with NZW mice (Bielschowsky *et al.*, *Proc. Univ. Otago Med. Sch.* 37:9, 1959; see also *Fundamental Immunology*, Paul, Ed., Raven Press,
20 New York, NY, 1989). Similarly, a shift to lethal nephritis is seen in the progeny of NBZ X SWR matings (Data *et al.*, *Nature* 263:412, 1976). The histological appearance of renal lesions in SNF₁ mice has been well characterized (Eastcott *et al.*, *J. Immunol.* 131:2232, 1983; see also *Fundamental Immunology*, *supra*). Therefore, the general health of the
25 animal as well as the histological appearance of renal tissue can be used to determine whether the administration of agents that target an IL-15R and, *e.g.*, target the IL-2R, can effectively suppress the immune response in an animal model of SLE.

One of the MRL strains of mice that develops SLE, MRL-*lpr/lpr*, also develops a form of arthritis that resembles rheumatoid arthritis in humans (Theofilopoulos
30 *et al.*, *Adv. Immunol.* 37:269, 1985). Alternatively, an experimental arthritis can be induced in rodents by injecting rat type II collagen (2 mg/ml) mixed 1:1 in Freund's

complete adjuvant (100 μ l total) into the base of the tail. Arthritis develops 2-3 weeks after immunization. The ability of nucleic acid molecules encoding agents of the invention (e.g., agents that target the IL-15R and agents that target the IL-2R or that bind to and inactivate antigen-activated T cells) to suppress an immune response can be assessed by targeting the nucleic acid molecules to T lymphocytes. One way to target T lymphocytes is as follows. Spleen cell suspensions are prepared 2-3 days after the onset of arthritis and incubated with collagen (100 μ g/ml) for 48 hours to induce proliferation of collagen-activated T cells. During this time, the cells are transduced with a vector encoding the polypeptide agent of interest. As a control, parallel cultures are grown but not transduced or, transduced with an "empty" vector. The cells are then injected intraperitoneally (5×10^7 cells/animal). The effectiveness of the treatment is assessed by following the disease symptoms during the subsequent 2 weeks, as described by Chernajovsky *et al.* (*Gene Therapy* 2:731-735, 1995). Lesser symptoms, compared to control, indicate that the combined agents of the invention, and the nucleic acid molecules that encode them, function as immunosuppressants and are therefore useful in the treatment of immune disease, particularly autoimmune disease.

The ability of various combinations of agents to suppress the immune response in the case of Type I diabetes can be tested in the BB rat strain, which was developed from a commercial colony of Wistar rats at the Bio-Breeding Laboratories in Ottawa. These rats spontaneously develop autoantibodies against islet cells and insulin, just as occurs with human Type I diabetes. Alternatively, NOD (non-obese diabetic) mice can be used as a model system. A typical example of an experiment in which blood sugar levels are restored in NOD mice following transplantation of allogeneic donor islets is described below and summarized in Fig. 11. The animals were treated with a combination of IL-2/Fc, IL-15/Fc, and rapamycin. The result was long-term engraftment.

Autoimmune diseases of the thyroid have been modeled in the chicken. Obese strain (OS) chickens consistently develop spontaneous autoimmune thyroiditis resembling Hashimoto's disease (Cole *et al.*, *Science* 160:1357, 1968). Approximately 15% of these birds produce autoantibodies to parietal cells of the stomach, just as in the human counterpart of autoimmune thyroiditis. The manifestations of the disease in OS chickens,

which could be monitored in the course of any treatment regime, include body size, fat deposit, serum lipids, cold sensitivity, and infertility.

Models of autoimmune disease in the central nervous system (CNS) can also be experimentally induced. An inflammation of the CNS, which leads to paralysis, can be induced by a single injection of brain or spinal cord tissue with adjuvant in many different laboratory animals, including rodents and primates. This model, referred to as experimental allergic encephalomyelitis (EAE) is T cell mediated. Similarly, experimentally induced myasthenia gravis can be produced by a single injection of acetylcholine receptor with adjuvants (Lennon *et al.*, *Ann. N.Y. Acad. Sci.* 274:283, 1976).

Autoimmune diseases of the gut can be modeled in IL-2 or IL-10 "knock out" mice, or in mice that receive enemas containing bovine serum albumin.

Nucleic Acid Molecules That Encode Agents of the Invention

Polypeptide agents of the invention, including those that are fusion proteins (e.g., the mutant IL-15/Fc and IL-2/Fc molecules) can not only be obtained by expression of a nucleic acid molecule in a suitable eukaryotic or prokaryotic expression system *in vitro* and subsequent purification of the polypeptide agent, but can also be administered to a patient by way of a suitable gene therapeutic expression vector encoding a nucleic acid molecule. Furthermore a nucleic acid can be introduced into a cell of a graft prior to transplantation of the graft. Thus, nucleic acid molecules encoding the agents described above are within the scope of the invention. Just as polypeptides of the invention can be described in terms of their identity with wild-type polypeptides, the nucleic acid molecules encoding them will necessarily have a certain identity with those that encode the corresponding wild-type polypeptides. For example, the nucleic acid molecule encoding a mutant IL-15 polypeptide can be at least 65%, preferably at least 75%, more preferably at least 85%, and most preferably at least 95% (e.g., 96%, 97%, 98%, or 99%) identical to the nucleic acid encoding wild-type IL-15. For nucleic acids, the length of the sequences compared will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides.

The nucleic acid molecules that encode agents of the invention can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy of the genetic code,⁸ encode the same polypeptide. These nucleic acid molecules can consist of RNA or DNA (for example, genomic DNA, cDNA, or synthetic DNA, such as that produced by phosphoramidite-based synthesis), or combinations or modifications of the nucleotides within these types of nucleic acids. In addition, the nucleic acid molecules can be double-stranded or single-stranded (*i.e.*, either a sense or an antisense strand).

The nucleic acid molecules of the invention are referred to as "isolated" because they are separated from either the 5' or the 3' coding sequence with which they are immediately contiguous in the naturally occurring genome of an organism. Thus, the nucleic acid molecules are not limited to sequences that encode polypeptides; some or all of the non-coding sequences that lie upstream or downstream from a coding sequence can also be included. Those of ordinary skill in the art of molecular biology are familiar with routine procedures for isolating nucleic acid molecules. They can, for example, be generated by treatment of genomic DNA with restriction endonucleases, or by performance of the polymerase chain reaction (PCR). In the event the nucleic acid molecule is a ribonucleic acid (RNA), molecules can be produced by *in vitro* transcription.

The isolated nucleic acid molecules of the invention can include fragments not found as such in the natural state. Thus, the invention encompasses recombinant molecules, such as those in which a nucleic acid sequence (for example, a sequence encoding a mutant IL-15) is incorporated into a vector (for example, a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell, at a position other than the natural chromosomal location).

As described above, agents of the invention can be fusion proteins. In addition to, or in place of, the heterologous polypeptides described above, a nucleic acid molecule encoding an agent of the invention can contain sequences encoding a "marker" or "reporter." Examples of marker or reporter genes include β -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo^r, G418^r), dihydrofolate reductase (DHFR), hygromycin-B-

phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding β -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT). As with many of the standard procedures associated with the practice of the invention, one of ordinary skill in the art will be aware of additional useful reagents, for example, of additional sequences that can serve the function of a marker or reporter.

The nucleic acid molecules of the invention can be obtained by introducing a mutation into an agent of the invention (e.g., an IL-15 molecule or an IL-2 molecule) obtained from any biological cell, such as the cell of a mammal, or produced by routine cloning methods. Thus, the nucleic acids of the invention can be those of a mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, monkey, baboon, dog, or cat. Preferably, the nucleic acid molecules will be those of a human.

The nucleic acid molecules described above can be contained within a vector that is capable of directing their expression in, for example, a cell that has been transduced with the vector. Accordingly, in addition to polypeptide agents, expression vectors containing a nucleic acid molecule encoding those agents and cells transfected with those vectors are among the preferred embodiments.

Vectors suitable for use in the present invention include T7-based vectors for use in bacteria (see, e.g., Rosenberg *et al.*, *Gene* 56:125, 1987), the pMSXND expression vector for use in mammalian cells (Lee and Nathans, *J. Biol. Chem.* 263:3521, 1988), yeast expression systems, such as *Pichia pastoris* (for example the PICZ family of expression vectors from Invitrogen, Carlsbad, CA) and baculovirus-derived vectors (for example the expression vector pBacPAK9 from Clontech, Palo Alto, CA) for use in insect cells. The nucleic acid inserts, which encode the polypeptide of interest in such vectors, can be operably linked to a promoter, which is selected based on, for example, the cell type in which expression is sought. For example, a T7 promoter can be used in bacteria, a polyhedrin promoter can be used in insect cells, and a cytomegalovirus or metallothionein promoter can be used in mammalian cells. Also, in the case of higher eukaryotes, tissue-specific and cell type-specific promoters are widely available. These promoters are so named for their ability to direct expression of a nucleic acid molecule in a given tissue or cell type within the body. One of ordinary skill in the art is well aware of numerous

promoters and other regulatory elements that can be used to direct expression of nucleic acids.

In addition to sequences that facilitate transcription of the inserted nucleic acid molecule, vectors can contain origins of replication, and other genes that encode a selectable marker. For example, the neomycin-resistance (*neo*^r) gene imparts G418 resistance to cells in which it is expressed, and thus permits phenotypic selection of the transfected cells. Other feasible selectable marker genes allowing for phenotypic selection of cells include various fluorescent proteins, e.g. green fluorescent protein (GFP) and variants thereof. Those of skill in the art can readily determine whether a given regulatory element or selectable marker is suitable for use in a particular experimental context.

Viral vectors that can be used in the invention include, for example, retroviral, adenoviral, and adeno-associated vectors, herpes virus, simian virus 40 (SV40), and bovine papilloma virus vectors (see, e.g., Gluzman (Ed.), *Eukaryotic Viral Vectors*, CSH Laboratory Press, Cold Spring Harbor, New York).

Prokaryotic or eukaryotic cells that contain a nucleic acid molecule that encodes an agent of the invention and express the protein encoded in that nucleic acid molecule *in vitro* are also features of the invention. A cell of the invention is a transfected cell, i.e., a cell into which a nucleic acid molecule, for example a nucleic acid molecule encoding a mutant IL-15 polypeptide, has been introduced by means of recombinant DNA techniques. The progeny of such a cell are also considered within the scope of the invention. The precise components of the expression system are not critical. For example, a mutant IL-15 polypeptide can be produced in a prokaryotic host, such as the bacterium *E. coli*, or in a eukaryotic host, such as an insect cell (for example, Sf21 cells), or mammalian cells (e.g., COS cells, CHO cells, 293 cells, NIH 3T3 cells, or HeLa cells). These cells are available from many sources, including the American Type Culture Collection (Manassas, VA). In selecting an expression system, it matters only that the components are compatible with one another. One of ordinary skill in the art is able to make such a determination. Furthermore, if guidance is required in selecting an expression system, one can consult Ausubel *et al.* (*Current Protocols in Molecular*

Biology, John Wiley and Sons, New York, NY, 1993) and Pouwels *et al.* (*Cloning Vectors: A Laboratory Manual*, 1985 Suppl. 1987).

Eukaryotic cells that contain a nucleic acid molecule that encodes the agent of the invention and express the protein encoded in such nucleic acid molecule *in vivo* are also features of the invention.

Furthermore, eukaryotic cells of the invention can be cells that are part of a cellular transplant, a tissue or organ transplant. Such transplants can comprise either primary cells taken from a donor organism or cells that were cultured, modified and/or selected *in vitro* before transplantation to a recipient organism (*e.g.*, eukaryotic cell lines, including stem cells or progenitor cells). Since, after transplantation into a recipient organism, cellular proliferation may occur, the progeny of such a cell are also considered within the scope of the invention. A cell, being part of a cellular, tissue or organ transplant, can be transfected with a nucleic acid encoding a mutant IL-15 polypeptide and subsequently be transplanted into the recipient organism, where expression of the mutant IL-15 polypeptide occurs. Furthermore, such a cell can contain one or more additional nucleic acid constructs allowing for application of selection procedures, *e.g.* of specific cell lineages or cell types prior to transplantation into a recipient organism.

The expressed polypeptides can be purified from the expression system using routine biochemical procedures, and can be used as diagnostic tools or as therapeutic agents, as described below.

Agents that Target an IL-15R are Useful in Making Diagnoses

Agents that target an IL-15R can be used to determine whether a patient has a disease (*e.g.*, an immune disease, particularly autoimmune disease) that is amenable to treatment with a combination of the agents described herein. The diagnostic method can be carried out, for example, by obtaining a sample of tissue from a patient suspected of having an immune disease, particularly autoimmune disease or a cancer that is manifest as malignant immune cells and exposing that tissue to an antigenically-tagged polypeptide that targets an IL-15R. The sample may be any biological sample, such as a blood, urine, serum, or plasma sample. In addition, the sample may be a tissue sample (*e.g.*, biopsy

tissue), or an effusion obtained from a joint (e.g., synovial fluid), from the abdominal cavity (e.g., ascites fluid), from the chest (e.g., pleural fluid), or from the central nervous system (e.g., cerebral spinal fluid). The sample may also consist of cultured cells that were originally obtained from a patient (e.g., peripheral blood mononuclear cells). The sample can be obtained from a mammal, such as a human patient. If the sample contains cells that are bound by the agent to which they are exposed, it is highly likely that they would be bound by that agent (e.g. an agent that targets an IL-15R) *in vivo* and could thereby be inhibited from proliferating or destroyed *in vivo*. The presenting symptoms of candidate patients for such testing and the relevant tissues to be sampled given a particular set of symptoms are well known to one of ordinary skill in the art.

Patients Amenable to Treatment

The compositions of the invention are useful in inhibiting T cells that are involved, or would be involved, in an immune response (e.g., a cellular immune response) to an antigen; in inhibiting other cells involved in the pathogenesis of immunological disorders (e.g., monocytes, macrophages, and other antigen presenting cells such as dendritic cells, NK cells, and granulocytes); and in destroying hyperproliferating cells (as seen, for example, in tissues involved in immunological disorders such as synovial fibroblasts (which are affected in rheumatoid arthritis) keratinocytes (which are affected in psoriasis), or dermal fibroblasts (which are affected in systemic lupus erythematosus). Given these examples, other cell types that can usefully be targeted will be apparent to those of ordinary skill in the art. Hyperproliferative cells may also be cancerous cells (e.g., malignant T cells).

Thus, the compositions of the invention can be used to treat patients who are suffering from an immune disease, particularly autoimmune disease, including but not limited to the following: (1) a rheumatic disease such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, scleroderma, mixed connective tissue disease, dermatomyositis, polymyositis, Reiter's syndrome or Behcet's disease (2) type I or type II diabetes (3) an autoimmune disease of the thyroid, such as Hashimoto's thyroiditis or Graves' Disease (4) an autoimmune disease of the central nervous system, such as

multiple sclerosis, myasthenia gravis, or encephalomyelitis (5) a variety of pemphigus, such as pemphigus vulgaris, pemphigus vegetans, pemphigus foliaceus, Senear-Usher syndrome, or Brazilian pemphigus, (6) diseases of the skin such as psoriasis or neurodermitis, and (7) inflammatory bowel disease (e.g., ulcerative colitis or Crohn's Disease). Combinations of the agents of the invention can also be used to treat acquired immune deficiency syndrome (AIDS). Similarly, methods by which these agents are administered can be used to treat a patient who has received a transplant of synthetic or biological material, or a combination of both. Such transplants can be organ, tissue or cell transplants, or synthetic grafts seeded with cells, for example, synthetic vascular grafts seeded with vascular cells. In addition, patients suffering from GVHD or patients who have received a vascular injury would benefit from this method.

Because the invention encompasses administration of a target-cell depleting form of an agent that targets the IL-15R (or an IL-2 receptor, or a combination of IL-15 or the IL-15R and IL-2 or the IL-2R), it is possible to selectively kill autoreactive or "transplant destructive" immune cells without massive destruction of normal T cells. Accordingly, the invention features a method of killing cells that express the IL-15R *in vivo*, which includes activated or autoreactive or "transplant destructive" immune cells or malignant cells. These methods can be carried out by administering to a patient a combination of agents that includes an agent that targets the IL-15R and that activates the complement system, lyses cells by the ADCC mechanism, or otherwise kills cells expressing the wild-type IL-15 receptor complex. This method can be used to treat patients who have IL-15R⁺ leukemia, lymphoma, or other IL-15R⁺ malignant diseases, such as colon cancer.

Formulations for Use and Routes of Administration

The methods of the present invention and the therapeutic compositions used to carry them out contain "substantially pure" agents. For example, in the event the agent is a polypeptide, the polypeptide is at least 60% by weight (dry weight) the polypeptide of interest, e.g., a polypeptide that binds and destroys IL-15R-bearing cells. Preferably, the agents (e.g., the polypeptides) are at least 75%, more preferably at least 90%, and most

preferably at least 99%, by weight, the agent of interest. Purity can be measured by any appropriate standard method, *e.g.*, column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

Although agents useful in the methods of the present invention can be obtained from naturally occurring sources, they can also be synthesized or otherwise manufactured (*e.g.*, agents that bind and destroy IL-15R-bearing cells can be produced by expression of a recombinant nucleic acid molecule). Polypeptides that are derived from eukaryotic organisms or synthesized in *E. coli*, or other prokaryotes, and polypeptides that are chemically synthesized will be substantially free from their naturally associated components. In the event the polypeptide is a chimera, it can be encoded by a hybrid nucleic acid molecule containing one sequence that encodes all or part of the agent (*e.g.*, a sequence encoding a mutant IL-15 polypeptide and sequence encoding an Fc region of IgG). Agents of the invention (*e.g.*, polypeptides) can be fused to a hexa-histidine tag to facilitate purification of bacterially expressed protein, or to a hemagglutinin tag to facilitate purification of protein expressed in eukaryotic cells.

The techniques that are required to make the agents of the invention are routine in the art, and can be performed without resort to undue experimentation by one of ordinary skill in the art. For example, a mutation that consists of a substitution of one or more of the amino acid residues in IL-15 can be created using the PCR-assisted mutagenesis technique described herein for the creation of the mutant IL-15 polypeptide in which glutamine residues at positions 149 and 156 were changed to aspartic acid residues. Mutations that consist of deletions or additions of amino acid residues (to an IL-15 polypeptide or to any of the other useful polypeptides described herein, *e.g.*, polypeptides that inhibit costimulation or that bind activated T cells) can also be made with standard recombinant techniques. In therapeutic applications, agents of the invention can be administered with a physiologically acceptable carrier, such as physiological saline. The therapeutic compositions of the invention can also contain a carrier or excipient, many of which are known to one of ordinary skill in the art. Excipients that can be used include buffers (*e.g.*, citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins

(e.g., serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. The agents of the invention can be formulated in various ways, according to the corresponding route of administration. For example, liquid solutions can be made for ingestion or injection; gels or powders can be made for ingestion, inhalation, or topical application. Methods for making such formulations are well known and can be found in, for example, "Remington's Pharmaceutical Sciences."

Routes of administration are also well known to skilled pharmacologists and physicians and include intraperitoneal, intramuscular, subcutaneous, and intravenous administration. Additional routes include intracranial (e.g., intracisternal or intraventricular), intraorbital, ophthalmic, intracapsular, intraspinal, intraperitoneal, transmucosal, topical, subcutaneous, and oral administration. It is expected that the intravenous or intra-arterial routes will be preferred for the administration of agents that target an IL-15 receptor. The subcutaneous route may also be used frequently as the subcutaneous tissue provides a stable environment for polypeptides, from which they can be slowly released.

In case of cell-based therapies (gene therapies), the cells/tissues/organs could either be transfected by incubation, infusion or perfusion prior to transplantation with a nucleic acid composition, such that the therapeutic protein is expressed and subsequently released by the transplanted cells/tissues/organs within the recipient organism. As well, the cells/tissues/organs could undergo a pretreatment by perfusion or simple incubation with the therapeutic protein prior to transplantation in order to eliminate transplant-associated immune cells adherent to the donor cells/tissues/organs (although this is only a side aspect, which will probably not be of any clinical relevance). In the case of cell transplants, the cells may be administered either by an implantation procedure or with a catheter-mediated injection procedure through the blood vessel wall. In some cases, the cells may be administered by release into the vasculature, from which the subsequently are distributed by the blood stream and/or migrate into the surrounding tissue (this is done in islet cells transplantation, where the islet cells are released into the portal vein and subsequently migrate into liver tissue).

It is well known in the medical arts that dosages for any one patient depend on many factors, including the general health, sex, weight, body surface area, and age of the patient, as well as the particular compound to be administered, the time and route of administration, and other drugs being administered concurrently. Dosages for the polypeptide of the invention will vary, but can, when administered intravenously, be given in doses on the order of magnitude of 1 microgram to 10mg/kg body weight or on the order of magnitude of 0.01mg/l to 100mg/l of blood volume. A dosage can be administered one or more times per day, if necessary, and treatment can be continued for prolonged periods of time. Determining the correct dosage for a given application is well within the abilities of one of ordinary skill in the art.

EXAMPLES

Reagents

The following reagents were used in the studies described herein: recombinant human IL-2 was obtained from Hoffman-La Roche (Nutley, NJ); rapamycin was obtained from Wyeth-Ayerst (Princeton, NJ); cyclosporine-A (CsA) was obtained from Sandoz (East Hanover, NJ); RPMI-1640 and fetal calf serum (FCS) were obtained from BioWittaker (Walkersville, MD); penicillin, streptomycin, G418, and streptavidin-RED670 were obtained from Gibco-BRL (Gaithersburg, MD); dexamethasone, PHA, lysozyme, Nonidet P-40, NaCl, HEPES, and PMSF were obtained from Sigma (St. Louis, MO); Ficoll-Hypaque was obtained from Pharmacia Biotech (Uppsala, Sweden); recombinant human IL-15 and anti-human IL-15 Ab were obtained from PeproTech (Rocky Hill, NJ); anti-FLAG Ab and anti-FLAG-affinity beads were obtained from International Biotechnologies, Inc. (Kodak, New Haven, CT); pRcCMV was obtained from InVitrogen Corporation (San Diego, CA); genistein was obtained from ICN Biomedicals (Irvine, CA); disuccinimidyl suberate (DSS) was obtained from Pierce (Rockford, IL); restriction endonucleases were obtained from New England Biolabs (Beverly, MA); [³H]TdR was obtained from New England Nuclear (Boston, MA); and fluorescent dye conjugated antibodies CD25-PE³, CD14-PE, CD16-PE, CD122-PE, CD4-FITC, CD8-FITC, IgG1-PE

or IgG1-FITC were obtained from Beckton/Dickinson (San Jose, CA). FLAG peptide was synthesized in the Peptide Synthesis Facility at Harvard Medical School.

Production of FLAG-HMK-IL-15 Fusion Protein

To study the cellular pattern of human IL-15 receptor expression, a plasmid
5 that could be used to express an IL-15 fusion protein was constructed. The plasmid encodes an IL-15 polypeptide having an N-terminus covalently bound to the 18 amino acid FLAG-HMK-sequence (FLAG-HMK-IL-15). FLAG sequences are recognized by biotinylated, highly specific anti-FLAG antibodies (Blanar *et al.*, *Science* 256:1014, 1992); LeClair *et al.*, *Proc. Natl. Acad. Sci. USA* 89:8145, 1992) while HMK (Heart
10 Muscle Kinase recognition site) sequences allow introduction of radioactive label [³²P] into the molecule (Blanar *et al.*, *supra*, LeClair *et al.*, *supra*).

For the construction of the plasmid FLAG-HMK-IL-15, a 322 bp cDNA fragment encoding mature IL-15 protein was amplified by PCR utilizing synthetic oligonucleotides [sense 5'-GGAATTCAACTGGGTGAATGTAATA-3' (SEQ ID NO:5;
15 *EcoRI* site (underlined) plus bases 145-162); antisense 5'-CGGGATCCTCAAGAAGTGTTGATGAA-3' (SEQ ID NO:5; *BamHI* site [underlined] plus bases 472-489)]. The template DNA was obtained from PHA-activated human PBMCs. The PCR product was purified, digested with *EcoRI* and *BamHI*, and cloned into the pAR(DRI)59/60 plasmid digested with *EcoRI*-*BamHI* as described (Blanar
20 *et al.*, *Science* 256:1014, 1992; LeClair *et al.*, *Proc. Natl. Acad. Sci. USA* 89:8145, 1992). The backbone of the pAR(DRI)59/60 plasmid contains in frame sequences encoding the FLAG and HMK recognition peptide sequences (Blanar *et al.*, *Science* 256:1014, 1992; LeClair *et al.*, *Proc. Natl. Acad. Sci. USA* 89:8145, 1992).

Expression and Purification of FLAG-HMK-IL-15 Fusion Protein

The IL-15-related fusion construct, FLAG-HMK-IL-15, was expressed in BL-21 strain *E. coli* and affinity purified with anti-FLAG coated beads as described (Blananar *et al.*, *Science* 256:1014, 1992; LeClair *et al.*, *Proc. Natl. Acad. Sci. USA* 89:8145, 1992).

5 The fusion protein was eluted from affinity columns after extensive washing with 0.1 M glycine (pH 3.0). The eluate containing FLAG-HMK-IL-15 was dialyzed against a buffer containing 50 mM Tris (pH 7.4) and 0.1 M NaCl for 18 hours at 4°C, filtered through a 0.2 µm membrane, and stored at -20°C.

FLAG-HMK-IL-15 binds the IL-15Rα subunit

10 The purified FLAG-HMK-IL-15 fusion protein was tested to determine whether it interacts with cell surface IL-15 receptors. As described above, [³²P]-FLAG-HMK-IL-15 was added to cultures of PBMCs that were activated by a mitogen, PHA. In order to permanently bind interactive proteins to one another, the chemical cross-linker disuccinimidyl suberate (DSS) was added. The cells were washed, lysed, centrifuged, and
15 detergent-soluble proteins were separated by SDS-PAGE. Autoradiography of SDS-PAGE separated proteins revealed a single 75-80 kDa band corresponding to the combined molecular weight of FLAG-HMK-IL-15 (15 kDa) and the human IL-15Rα subunit (60-65 kDa). The identity of this band as the IL-15Rα subunit was confirmed by cross-linking experiments conducted in the presence of a molar excess of hIL-15. Under
20 these conditions, we failed to detect the radio labeled 15 kDa band. Thus, the conformation of [³²P]-FLAG-HMK-IL-15 fusion proteins allows site specific binding to the 60-65 kDa IL-15Rα subunit expressed on the surface of mitogen-activated PBMCs.

FLAG-HMK-IL-15 is a Biologically Active Growth Factor that Requires Expression of IL-2Rβ

In the next series of experiments, the FLAG-HMK-IL-15 fusion protein was tested to determine whether it could function as a biologically active growth factor. PHA-activated human PBMCs proliferate in response to either FLAG-HMK-IL-15 or human recombinant IL-2, as detected via the [^3H]-TdR incorporation assay. A FLAG peptide lacking the IL-15 sequence does not stimulate cell proliferation. As does IL-2, the FLAG-HMK-IL-15 fusion protein stimulates proliferation of IL-2R γ^+ BAF-BO3 cell transfectants that express the IL-2R β subunit. The FLAG-HMK-IL-15 fusion protein does not, however, stimulate the proliferation of parental BAF-BO3 cells that were transfected with a vector lacking IL-2R β chain sequences. Thus, FLAG-HMK-IL-15 is a biologically active growth factor that requires expression of IL-2R β chains upon target cells in order to stimulate cellular proliferation.

Mitogen-activated, but not Resting, PBMCs Express the IL-15R α Subunit

The FLAG-HMK-IL-15 fusion protein, biotinylated anti-FLAG antibody, and streptavidin-RED670 were employed to detect expression of IL-15 binding sites on human PBMCs by cytofluorometric analysis. The PBMCs tested were either freshly isolated or PHA-activated. These cells were washed and incubated with either medium alone or FLAG-HMK-IL-15 followed by anti-FLAG biotinylated Ab and streptavidin-RED670. The stained cells were analyzed by flow cytometry. PBMCs that were activated with PHA expressed IL-15R α proteins but resting PBMCs did not. In keeping with the result of the cross-linking experiments described above, binding of FLAG-HMK-IL-15 to PHA activated PBMCs is blocked by a molar excess of rIL-15, thereby demonstrating the specificity of FLAG-HMK-IL-15 binding for IL-15 binding sites. Both activated CD4 $^+$ and CD8 $^+$ cells express IL-15 α chains. Activation induced IL-15R α chains were also detected on CD14 $^+$ (monocyte/macrophage) cells and CD16 $^+$ (natural killer) cells.

IL-2R α and IL-2R β Subunits Are Not Required for IL-15 Binding

FACS analysis of PHA-activated PBMCs stained with FLAG-HMK-IL-15 proteins and anti-CD25 Mab, against the IL-2R α subunit, reveals cell populations expressing both IL-15R α and IL-2R α subunits, as well as cell populations that express either subunit, but not both. There are IL-2R α ⁺ cells that do not bind FLAG-HMK-IL-15. Almost all PBMCs that were stimulated with PHA for only one day express either IL-15R α or IL-2R β chains, but not both proteins. In contrast, 3 days following PHA stimulation, a far larger population of IL-15R α ⁺, IL-2R β ⁺ cells (double positive) and a far smaller population of IL-15R α ⁺, IL-2R β ⁻ cells (single positive) were noted. Interestingly, there are IL-2R β ⁺ cells that fail to bind IL-15. Therefore, expression of IL-2R β chains is not sufficient for IL-15 binding.

Taken together, these data indicate that IL-15 can bind IL-15R α ⁺, IL-2R α ⁻, and IL-2R β ⁻ cells. A similar conclusion was reached through experimentation that probed the interaction of IL-15 with IL-2R α ⁻, β ⁻ cells transfected with IL-15R α subunit (Anderson *et al.*, *J. Biol. Chem.* **270**:29862, 1995; Giri *et al.*, *EMBO J.* **14**:3654, 1995). In addition to the requirement for IL-15R α subunit expression, the IL-2R β and IL-2R γ subunits are required to render cells sensitive to IL-15 triggered growth.

In summary, the experiments presented above have demonstrated that: (i) IL-15R α subunits are rapidly expressed by activated macrophages, T cells, and NK cells, and (ii) induction of the IL-15R α subunit is blocked by dexamethasone but not by CsA or rapamycin. In addition, the experiments have confirmed that the IL-15R α subunit is necessary and sufficient for IL-15 binding and that the FLAG-HMK-IL-15 fusion protein is an extremely useful tool for studying IL-15 receptors.

The IL-2R β Subunit is Critical for both IL-2 and IL-15 Signal Transduction

Decreasing the viability of activated T cells and thereby depleting activated T cells provides a way to decrease the production of lymphokines and mitogens that contribute to accelerated atherosclerosis, allograft rejection, certain leukemias and other immune-mediated pathologies. In addition, blocking the signal transduction pathway activated by IL-15 also provides a way to decrease the production of lymphokines and

mitogens that contribute to accelerated atherosclerosis, allograft rejection, certain leukemias and other immune-mediated pathologies. When activated, T cells proliferate and express receptors on their cell surface for interleukins. In addition, activated T cells release at least 3 lymphokines: gamma interferon, B cell differentiation factor II, and IL-3. These lymphokines can produce various undesirable events, such as allograft rejection. In contrast, resting T cells and long-term memory T cells do not express lymphokine receptors. This difference in receptor expression provides a means to target activated immune cells without interfering with resting cells. Molecules designed to recognize some subunit of the IL-15R will recognize activated monocytes/macrophages as well as activated T cells and can be used to selectively inhibit or destroy these cells. Derivatives of IL-15 that bind to an IL-15R subunit but that lack IL-15 activity, either because they block the binding and/or uptake of bona fide IL-15, are useful in the method of the invention. The mutant IL-15 molecule described below provides a working example of such a derivative.

A Mutant IL-15 Polypeptide that Targets an IL-15R

Genetic Construction of mutant IL-15

The human IL-15 protein bearing a double mutation (Q149D; Q156D) was designed to target the putative sites critical for binding to the IL-2R γ subunit. The polar, but uncharged glutamine residues at positions 149 and 156 were mutated into acidic residues of aspartic acid utilizing PCR-assisted mutagenesis. A cDNA encoding the double mutant of IL-15 was amplified by PCR utilizing a synthetic sense oligonucleotide [5'-GGAATTCAACTGGGTGAATGTAATA-3' (SEQ ID NO:); *EcoRI* site (underlined hexamer) plus bases 145-162] and a synthetic antisense oligonucleotide (5'-CGGGATCCTCAAGAAGTGTGATGAACATGTCGACAAT-ATGTACAAAACTGTC $\overline{\text{C}}$ AAAAAT-3' (SEQ ID NO:); *BamHI* site (underlined hexamer) plus bases 438-489; mutated bases are singly underlined]. The template was a plasmid containing cDNA that encodes human FLAG-HMK-IL-15. The amplified fragment was digested with *EcoRI/BamHI* and cloned into the pAR(DRI)59/60 plasmid digested with *EcoRI/BamRI* as described (LeClair *et al.*, *Proc. Natl. Acad. Sci. USA*

89:8145, 1989). The presence of a mutation at residue 156 was confirmed by digestion with *Sall*; the mutation introduces a new *Sall* restriction site. In addition, mutations were verified by DNA sequencing, according to standard techniques. The FLAG-HMK-IL-15 (Q149D; Q156D) double mutant protein was produced, purified, and verified by sequencing as described above for the FLAG-HMK-IL-15 wild-type protein.

Using this same strategy, mutants that contain a single amino acid substitution, either at position 149 or at position 156 were prepared. As described above, these positions (149 and 156) correspond to positions 101 and 108, respectively, in the mature IL-15 polypeptide, which lacks a 48-amino acid signal sequence.

Similarly, this strategy can be used to incorporate any other amino acid in place of the glutamine residues at positions 149 or 156 or to introduce amino acid substitutions at positions other than 149 and/or 156.

Proliferation of BAF-BO3 Cells in the Presence of IL-15 Related Proteins

The double mutant IL-15 polypeptide may inhibit BAF-BO3 proliferation in a dose-dependent manner: addition of 30 μ l (approximately 50 μ g/ml) of the double mutant IL-15 inhibited proliferation more completely than did addition of 20 μ L of the same concentration of the double mutant IL-15.

Proliferation of PHA-Stimulated Human PBMCs

The ability of the FLAG-HMK-IL-15 double mutant polypeptide to bind PHA activated human PBMCs was demonstrated as follows. PHA-activated PBMCs were washed and incubated with medium alone, or with the FLAG-HMK-IL-15 double mutant. The cells were then incubated with an anti-FLAG biotinylated antibody and stained with streptavidin conjugated to RED670. The stained cells were analyzed by flow cytometry.

FACS Analysis of Leukemic Cell Lines Stained with Wild-Type FLAG-HMK-IL-15

In a series of experiments similar to those above, the ability of the wild-type FLAG-HMK-IL-15 polypeptide to bind leukemia cells was shown. The cells treated were obtained from the leukemic cell lines MOLT-14, YT, HuT-102, and from cell lines currently being established at Beth Israel Hospital (Boston, MA), and named 2A and 2B. The cultured cells were washed and incubated with either medium alone or with medium containing the FLAG-HMK-IL-15 wild-type polypeptide. The cells were then incubated with the biotinylated anti-FLAG antibody and stained with RED670-conjugated streptavidin. The stained cells were analyzed by flow cytometry.

Genetic Construction of Additional Mutant IL-15 Chimeric Polypeptides

In addition to the FLAG-HMK-IL-15 chimera, which provides the mutant IL-15 with an antigenic tag, numerous other polypeptides can be linked to any mutant of IL-15 or IL-2. For example, mutant IL-15 or IL-2 can be linked to the Fc fragment of the IgG subclass of antibodies according to the following method.

Genetic Construction of Mutant IL-15/Fc

cDNA for Fcγ2a can be generated from mRNA extracted from an IgG2a secreting hybridoma using standard techniques with reverse transcriptase (MMLV-RT; Gibco-BRL, Grand Island, NY) and a synthetic oligo-dT (12-18) oligonucleotide (Gibco BRL). The mutant IL-15 cDNA can be amplified from a plasmid template by PCR using IL-15 specific synthetic oligonucleotides.

The 5' oligonucleotide is designed to insert a unique *NotI* restriction site 40 nucleotides 5' to the translational start codon, while the 3' oligonucleotide eliminates the termination codon and modifies the C-terminal Ser residue codon usage from AGC to TCG to accommodate the creation of a unique *BamHI* site at the mutant IL-15/Fc junction. Synthetic oligonucleotides used for the amplification of the Fcγ2a domain cDNA change the first codon of the hinge from Glu to Asp in order to create a unique

*Bam*HI site spanning the first codon of the hinge and introduce a unique *Xba*I site 3' to the termination codon.

The Fc-fragment can be modified so that it is non-target-cell depleting, *i.e.*, not able to activate the complement system. To make the non-target-cell depleting mutant IL-15 construct (mIL-15/Fc), oligonucleotide site directed mutagenesis is used to replace the C'1q binding motif Glu318, Lys320, Lys322 with Ala residues. Similarly, Leu235 is replaced with Glu to inactivate the FcγR I binding site. Ligation of cytokine and Fc components in the correct translational reading frame at the unique *Bam*HI site yields a 1,236 basepair open reading frame encoding a single 411 amino acid polypeptide (including the 18 amino acid IL-15 signal peptide) with a total of 13 cysteine residues. The mature secreted homodimeric IL-15/Fc is predicted to have a total of up to eight intramolecular and three inter-heavy chain disulfide linkages and a molecular weight of approximately 85 kDa, exclusive of glycosylation.

15 Expression and Purification of mIL-15 Receptor Fc Fusion Proteins

Proper genetic construction of mIL-15/Fc can be confirmed by DNA sequence analysis following cloning of the fusion gene as a *Not*I-*Xba*I cassette into the eukaryotic expression plasmid pRc/CMV (Invitrogen, San Diego, CA). This plasmid carries a CMV promoter/enhancer, a bovine growth hormone polyadenylation signal and a neomycin resistance gene for selection with G418. Plasmids carrying the mIL-15/Fc fusion gene is transfected into Chinese hamster ovary cells (CHO-K1, available from the American Type Culture Collection) by electroporation (1.5 kV/3 μF/0.4 cm/PBS) and selected in serum-free Ultra-CHO media (BioWhittaker Inc., Walkerville, MD) containing 1.5 mg/ml of G418 (Geneticin, Gibco BRL). After subcloning, clones that produce high levels of the fusion protein are selected by screening supernatants from IL-15 by ELISA (PharMingen, San Diego, CA). mIL-15/Fc fusion proteins are purified from culture supernatants by protein A sepharose affinity chromatography followed by dialysis against PBS and 0.22 μm filter sterilization. Purified proteins can be stored at -20°C before use.

Western blot analysis following SDS-PAGE under reducing (with DTT) and non-reducing (without DTT) conditions can be performed using monoclonal or polyclonal

anti-mIL-15 or anti Fc γ primary antibodies to evaluate the size and isotype specificity of the fusion proteins. The functional activity of mutant IL-15/Fc can be assessed by a standard T cell proliferation assay, as described above. The following mAbs were obtained from PharMingen (San Diego, CA): PE-anti-mouse CD25 (IL-2R α chain, IgG1, PC61), rat anti-mouse CD122 (IL-2R β chain, IgG2b, TM-b1), rat anti-mouse CD132 (IL-2R γ c, IgG2b, TUGm2), hamster anti-mouse CD3 (IgG, 145-2C11), hamster anti-mouse CD28 (IgG, 37.51), PE-anti-mouse CD62L (IgG2a, MEL14), PE conjugated hamster anti-mouse Bcl-2 (IgG, 3F11), PE conjugated anti-mouse IL-2 (IgG2b, JES6-5H4), PE-annexin V, biotinylated anti-rat IgG2b, PE-streptoavidin, PE-CyChrome, and PE conjugated isotype control mAbs. A biotinylated mouse anti-FLAG mAb and a rat IgG1 control mAb were obtained from Sigma Chemical Co. (St Louis, MO). A B-cell hybridoma secreting rat anti-mouse CD25 mAb (TIB 222, IgG1) was obtained from the American Type Culture Collection (ATCC; Manassas, VA). Cells were grown in serum free UltraCulture medium (BioWhittaker, Walkerville, MD) and the mAb in the culture supernatant was purified with a protein G column.

Expression Studies of IL-2 and IL-15 *in vivo*.

Recombinant human IL-2 and IL-15 were purchased from R & D System (Minneapolis, MN). IL-15-FLAG and IL-15 mutant/Fc fusion proteins were constructed, expressed, and tested as previously reported (Chae *et al.*, *J. Immunol.* 157:2813-2819, 1996; Kim *et al.*, *J. Immunol.* 161:5742-5748, 1998). Rat anti-mouse γ c mAbs (4G3/3E12, IgG2b) were used as previously reported (Li *et al.* *J. Immunol.* 164:1193-1199, 2000).

Lymphocytes were labeled with fluorochrome 5-carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Inc., Portland, OR) as follows. Spleens and peripheral lymph nodes were harvested from donor mice and single cell suspensions were prepared in Hanks balanced salt solution (HBSS). Red blood cells were lysed by hypotonic shock. Cells were resuspended in HBSS at 1×10^7 /ml and labeled with CFSE as described by Wells *et al.* (*J. Clin. Invest.* 100:3173-3183, 1997).

To activate CFSE-labeled T cells *in vivo*, DBA/2 mice were irradiated (1000 rad) with a Gammacell Exactor (Kanata, Ontario, Canada). Each mouse then received 4 to 6×10^7 CFSE-labeled cells in 0.5 ml HBSS via the tail vein. Three days later, the host mice were sacrificed and spleens and peripheral lymph nodes were harvested separately. Single cell suspensions were prepared for cell surface staining and FACS analysis.

In some experiments, irradiated host mice were treated with anti-CD25 mAb or anti- γc mAbs (i.p. at 1mg/day for 3 days starting at i.v. injection of CFSE-labeled cells). Cell division *in vivo* was determined on the third day following injection of CFSE-labeled cells. Treatment with IL-15 mutant /Fc fusion protein consisted of 1.5 μ g i.p. daily, for three days, starting at i.v. injection of labeled cells.

CFSE-labeled cells activated *in vivo* in irradiated allogeneic hosts were stained for the expression of IL-2 and IL-15 receptor subunits. To detect IL-2 receptor α chain expression, cells (2×10^6) were stained with PE-anti-mouse CD25 mAb on ice for 30 minutes, washed, and resuspended in 1 ml PBS containing 0.5% BSA. To detect IL-2R β and γc expression, cells were incubated with a rat anti-mouse β chain (IgG2b) or γc mAb (IgG2b) on ice for 30 minutes, followed by incubation with a biotinylated anti-rat IgG2b. Cells were washed and further stained with PE-streptoavidin for 20 minutes. Cells were washed and resuspended in PBS-0.5% BSA for analysis. To detect IL-15R α chain expression, cells were incubated with an IL-15-FLAG fusion protein that binds to the α chain (Chae *et al.*, *J. Immunol.* 157:2813-2819, 1996) and then stained with biotinylated mouse anti-FLAG mAb. The cells were then washed and stained with PE-streptoavidin. Isotype matched control mAbs were included in each experiment as a control. All samples were analyzed using FACSort with CellQuest™ software (Becton Dickinson, Mountain View, CA). Data were collected and analyzed by gating onto CFSE⁺ cells. All dividing CFSE⁺ cells were T cells, as defined by the expression of CD3. At least 100,000 events were collected for each sample.

Apoptosis of dividing T cells *in vivo* was analyzed as follows. CFSE-labeled lymphocytes were stimulated *in vivo* in irradiated allogeneic hosts as described above. Cells were harvested from the host spleen or peripheral lymph nodes three days later and stained with PE conjugated annexin V on ice for 15 minutes in labeling buffer. Cell

division was identified based on the cells' CFSE profile, and apoptotic cell death in each distinct cell division was analyzed by annexin V staining.

Cells were also stained for intracellular IL-2 and Bcl-2 cytokine expression. CFSE-labeled cells that had been activated *in vivo* for three days were harvested from the host spleen and lymph nodes. Cells were restimulated *in vitro* with PMA (50 ng/ml) and ionomycin (500 ng/ml) for four hours and GolgiStop™ (PharMingen) was added for the last two hours of culture. Cells were fixed and permeablized with Cytofix/Cytoperm (PharMingen) at 4°C for 10 minutes, and then stained with PE-conjugated anti-mouse IL-2 mAb, isotype matched control mAb was included as a control. For Bcl-2 staining, cells were fixed and permeablized with Cytofix/Cytoperm for 10 minutes and stained with PE-conjugated anti-Bcl-2 mAb or isotype control Ab for 30 minutes. Cells were washed and analyzed by FACS.

Cell sorting and *in vitro* re-stimulation was carried out as follows. CFSE-labeled cells were prepared from irradiated allogeneic hosts three days after i.v. injection of labeled cells. Cell proliferation *in vivo* was identified through analysis of their CFSE profiles. The second cell divisions were selected, gated, and sorted with FACS Vantage™ sorter (Becton Dickinson) at 2000 events/second. The sorted cells were resuspended in RPMI 1640 medium supplemented with 10% FCS and 1% penicillin and streptomycin at 5×10^5 /ml and plated on anti-CD3 (2 µg/ml) coated plates along with anti-CD28 mAb (1 µg/ml). Three days later, cells were harvested and stained with PE-conjugated anti-mouse CD25 and isotype control Ab. Cell proliferation and IL-2 receptor α chain expression were analyzed by FACS.

Cell sorting and *in vitro* proliferation assays were carried out as follows. CFSE-labeled cells were prepared from irradiated allogeneic hosts three days after intravenous injection of labeled cells, and cell proliferation *in vivo* was identified by analysis of the cells' CFSE profile. The second cell division was selected, gated, and sorted with FACS Vantage™. Cells (1×10^4 /ml) were resuspended in RPMI 1640 medium with 10% FCS and 1% penicillin and streptomycin, and stimulated with IL-2 (40 µ/ml to 500 µ/ml) or IL-15 (5 ng/ml) for 48 hours. Cells were pulsed with 1 mCi 3H-TdR (Amersham, Boston, MA)

for 16 hours and ^3H -TdR uptake was determined by scintillation counting (Beckman Instrument, Columbia, MD).

The reagents and techniques described above provided the basis for several findings. First, CFSE-labeled B6AF1 (H-2b/d.k) allogeneic lymphocytes, in contrast to syngeneic controls (Li *et al.*, *Nature Medicine* 5:1298-1302, 1999), proliferated vigorously in irradiated DBA/2 (H-2d) hosts. Approximately 20% of the CFSE-labeled T cells recovered from the host spleen entered the cell cycle within three days of adoptive transfer, and seven to eight discrete rounds of cell division were clearly identified (Fig. 3A). Surprisingly, the IL-2 receptor α chain, which is required for high affinity IL-2 receptor signaling, could not be detected during the first 5 divisions, *i.e.*, this receptor subunit is expressed only after five cell divisions. In contrast, β subunits of the IL-2 receptor were expressed constitutively by all dividing T cells, and their level of expression was increased progressively as cells continued to divide. The pattern of γ c expression *in vivo* differed strikingly from that of the α chain and the β chain (Fig. 3A). Undivided T cells (0 division) expressed very low levels of γ chain (<10%). Following entry into the cell cycle, γ chain was highly expressed by dividing T cells, and the levels of expression continued to increase after each consecutive cell division. After five cell divisions, however, γ chain expression was drastically down regulated, nearly reaching the basal level after the sixth cell division (Fig. 3A).

The differential expression of IL-2 receptor subunits is not due to selective accumulation of a subset of activated T cells in the host spleen, as CFSE-labeled cells harvested from peripheral lymph nodes displayed a remarkably similar pattern of expression for the three subunits of the IL-2 receptor.

Second, stimulation of CFSE-labeled T cells *in vitro* resulted in a uniform expression of all three subunits of the IL-2 receptor (Fig. 3B). This suggests that regulation of IL-2 receptor expression *in vivo* is distinct from that *in vitro*. The IL-2 receptor α chain is known to be sensitive to proteolytic cleavage *in vivo* in a manner that is similar to the selectins (Hemar *et al.*, *J. Cell. Biol.* 129:55-64, 1995). Staining for L-selectin expression by dividing T cells *in vivo* showed that L-selectin was expressed at high levels during the first five cell divisions (Fig. 3C), suggesting that the failure to

detect IL-2 receptor α chain expression during the first five cell divisions is not due to rapid proteolytic cleavage. To determine whether T cells in the first five cell divisions are capable of expressing the IL-2 receptor α chain, T cells at the second cell division, which did not express IL-2 receptor α chain, were sorted and stimulated *in vitro* with
5 immobilized anti-CD3 and soluble anti-CD28 for three days. These sorted T cells continued to divide upon *in vitro* restimulation, and all dividing T cells expressed the IL-2 receptor α chain. Clearly, expression of IL-2 receptor α chain *in vivo* and *in vitro* is differentially regulated.

As the receptor for IL-15 also uses the IL-2 receptor β and γ chains as critical
10 signaling components (Tagaya *et al.*, *Immunity* 4:329-336, 1996), which are highly expressed during the first five cell divisions, we asked whether cells express an IL-15 receptor α chain that renders them responsive to IL-15 during initial cell divisions. Application of an IL-15-FLAG fusion protein as a primary staining reagent (Chae *et al.*, *J. Immunol.* 157:2813-2819, 1996), demonstrated that the IL-15 receptor α chain is clearly
15 detectable, albeit at low levels, on dividing T cells regardless the number of cell divisions (Fig. 4A). The α chain for IL-2 receptor was not detected on all dividing T cells *in vivo*. Thus, selective expression of the α chain for IL-15 receptor, but not for IL-2 receptor, along with the expression of shared β and γ chains during the first five cell divisions, suggests that initial cell division *in vivo* is likely IL-15- but not IL-2-dependent.

20 To test this hypothesis, IL-2 production was assessed in dividing T cells *in vivo*. Intracellular IL-2 staining revealed that IL-2 was highly expressed only by cells that have divided more than five times. Treatment of host mice with saturating doses of cytolytic anti-CD25 mAb failed to inhibit the first five cell divisions (relative to control Ab treated mice), and dividing cells in the first and fifth divisions were remarkably similar in anti-
25 CD25 treated mice and in control mice. Furthermore, T cells at the second cell division *in vivo* were sorted and cultured *in vitro* in the presence of IL-2 or IL-15, and cell proliferation was analyzed by ^3H -TdR uptake. IL-2, provided in doses as high as 500 u/ml in culture, failed to support T cell proliferation. In contrast, IL-15 stimulated vigorous cell proliferation (Fig. 4B).

The pattern of IL-2 expression *in vivo* is closely associated with upregulation of the IL-2 receptor α and β chains, and with markedly decreased expression of the common γ chain (Fig. 5A). This suggests that IL-2 regulates γ chain expression *in vivo*. To test this possibility, γ chain expression was examined in T cells from IL-2 deficient mice and wild type control mice. CD4⁺ T cells from IL-2 deficient mice expressed very high levels of γ chain on the cell surface as compared to wild type controls (Fig. 5B). Treatment of host mice with anti-CD25 inhibited γ chain down regulation on dividing T cells *in vivo*, but this treatment had no effect on IL-2 receptor β chain expression (Fig. 5C).

The γ chain is a critical signaling element for all known T cell growth factors and γ chain signals are essential for cell survival, which is accomplished at least in part via sustained expression of Bcl-2 family anti-apoptotic proteins (Nakajima *et al.*, *J. Exp. Med.* 185:189-195, 1997). To determine whether decreased γ chain expression after five cell divisions *in vivo* regulates clonal expansion, CFSE-labeled cells were stained with PE-annexin V after recovery from the hosts and apoptotic cell death of dividing T cells was analyzed *in vivo*. Precipitous cell death occurred after four cell divisions. Undivided cells (0 division) had <10% annexin V positive cells. After the sixth cell division, however, ~40% of the cells were annexin V positive. This type of cell death is not Fas dependent, as T cells from Fas mutant MRL-lpr mice had similar pattern of apoptotic cell death *in vivo* (Li *et al.*, *J. Immunol.* 163:2500-2507, 1999). Staining for Bcl-2 expression showed that the mean channel fluorescence intensity of Bcl-2 staining was markedly decreased after four cell divisions (Fig. 5E). Thus, the signaling events upon γ chain down-regulation may fail to support sustained Bcl-2 expression and cells become susceptible to apoptotic cell death (Nakajima *et al.*, *J. Exp. Med.* 185:189-195, 1997).

These results suggest that blocking IL-2 or IL-15 signaling will have different effects on T cell expansion *in vivo*. To explore this possibility further, CFSE-labeled lymphocytes from IL-2 deficient mice (H-2b) were injected into irradiated DBA/2 hosts (H-2d), cell division was analyzed *in vivo* three days later and compared with that in wild type control mice. T cells from IL-2 deficient mice continued to divide and expand *in vivo*. About 30% of CFSE-labeled cells entered the cell cycle, and the majority of the cells divided more than five times, compared to control.

Treating host mice with an IL-15 mutant /Fc, which acts as an IL-15 receptor specific antagonist (Kim *et al.*, *J. Immunol.* 161:5742-5748, 1998), markedly reduced the proliferation frequency of CFSE-labeled T cells, and an overwhelming majority of CFSE-labeled cells failed to enter the cell cycle in the treated mice. Furthermore, treatment of host mice with blocking mAbs against the common γ chain, a shared signaling component of IL-2 and IL-15 receptors, also markedly inhibited T cell division *in vivo*. Thus, IL-2 and IL-15 regulate distinct aspects of T cell expansion *in vivo*, and administration of antagonists for these interleukins can suppress the immune response, as discussed above.

These results also demonstrate that γ chain downregulation requires T cell activation and cell cycle progression as well as IL-2 signaling. Clearly, γ chain downregulation *in vivo* is closely associated with IL-2 production and high affinity IL-2 receptor expression. In the absence of IL-2, γ chain is expressed at extremely high levels and blockade of IL-2 receptor inhibits γ chain downregulation *in vivo* on cycling T cells. Thus, these studies provide novel evidence that IL-2 and IL-15 regulate distinct aspects of primary T cell activation *in vivo*. Contrary to traditional beliefs and conclusions based on *in vitro* studies, IL-15 is a critical growth factor in initiating T cell division *in vivo* and IL-2's unique role *in vivo* is to control the magnitude of clonal expansion by regulating γ chain expression on cycling T cells.

These results support the clinical applications described above. Attempts to boost T cell response with exogenous IL-2 in tumor immunity and AIDS may promote premature T cell death and therapies to block IL-2 in tolerance induction and autoimmunity may induce unwanted T cell expansion. Furthermore, staged and combined targeting of IL-15 and IL-2 represent an important way to block T cell activation in T cell dependent cytopathic conditions.

Lytic IL-2/Fc lyses IL-2R-bearing cells and binds to FcRI

Cells of a T cell line (CTLL-2 cells; 10^6) were labeled with 100 mCi ^{51}Cr and incubated with a lytic form of IL-2/Fc and rat low-toxic complement (C'), a non-lytic form of IL-2/Fc and C', murine immunoglobulin and C' (a negative control) or C' alone (a negative control at 0.5 $\mu\text{g/ml}$). Another group of the same cells was treated with a

detergent (1% NP40)(a positive control). Cell lysis was measured by ^{51}Cr release. The degree of lysis observed in the presence of the detergent represents 100% lysis. Specific lysis following treatment as described above was calculated according to the formula: % specific lysis = [(experimental cpm - background cpm)/(total release cpm - background cpm) x 100%]. The results, which are shown in Fig. 6, support the conclusion that

To assess the ability of lytic and nonlytic IL-2/Fc to bind Fc receptors on FcRI-transfected CHO cells (murine FcRI, FcRII, and IL-2R-negative), FcRI transfectants were pre-incubated with PBS, mIgG2a, lytic IL-2/Fc, or nonlytic IL-2/Fc. After washing, fluorescent-conjugated goat anti-mouse Fc was used to stain the cells for FACS analysis. As shown in Fig. 7, cytolytic IL-2/Fc can bind FcRI, but lytic IL-2/Fc cannot.

Lytic IL-2/Fc is effective in preventing diabetes in an adoptive transfer model

Two different variants of IL-2/Fc were created. The first contained an Fc terminus derived from murine IgG2a that will mediate CDC and CDCC (IL-2/Fc), and the second was a point mutated Fc portion that would not activate CDC or CDCC (IL-2/Fc-/-). Whereas IL-2/Fc mediates CDC in IL-2R bearing cells (such as those of the murine CTLL-2 T cell line) and binds to FcRI, IL-2/Fc-/- does not (Figs. 6 and 7). Moreover, the lytic IL-2/Fc molecule will prevent the development of diabetes in an NOD adoptive transfer model, but a non-lytic form of the molecule (IL-2/Fc-/-) is ineffective (Fig. 13). In the animal model, monodispersed spleen cells were depleted of erythrocytes by treatment with ACK Lysing Buffer (BioWhittaker Inc., Walkersville, MD). Eight to 12 week-old irradiated (700-rad) NOD male recipients, which were non-diabetic, were then injected with 2×10^7 splenic leukocytes from acutely diabetic female NOD mice (hyperglycemia < two weeks). Blood glucose levels (BGL) were tested weekly, and diabetes was diagnosed when the BGL was greater than 16.5 mmol/L on any single measurement or greater than 13.8 mmol/L on 3 consecutive days. As shown in Fig. 13, most of the animals remained diabetes free even after the treatment was discontinued.

As noted above, the assays and animal models presented herein can be used to test various combinations of the agents of the invention for therapeutic efficacy.

Rapamycin inhibits T cell proliferation in an in vivo graft versus host model, but does not inhibit apoptosis of activated T cells

In an *in vivo* graft versus host model (as described above), the fate of host reactive T cells in the presence of IL-2/Fc and rapamycin was analyzed. As shown in Fig. 8, rapamycin will inhibit the proliferation of CD4⁺ and CD8⁺ T cells, even in the presence of IL-2/Fc, but will allow the expression of a functional IL-2R. As evidenced by Annexin V staining, antigen activated host reactive T cells will undergo apoptosis in the presence of IL-2/Fc and rapamycin (Fig. 10).

The compositions of the invention permit long-term survival of islet and skin allografts

To prevent rejection of either allogeneic islets transplanted into acutely diabetic NOD recipients or rejection of skin grafts transplanted onto NOD mice, a combination of agents promoting T cell death and inhibiting T cell proliferation was used. As shown in Figs. 11 and 12, a combination of lytic IL-2/Fc, mutIL-15/Fc and rapamycin proved effective in preventing graft rejection (and more effective than other treatment regimens tested). Graft survival and graft function persisted throughout the observation period shown, and most grafts survived after discontinuation of the therapy. This dramatic effect is believed to be due to the combination of agents used (agents that promote T cell death as well as inhibit T cell proliferation).

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

1 WHAT IS CLAIMED IS:

2 1. A therapeutic composition comprising a first agent that targets an interleukin-
3 15 receptor (IL-15R) and a second agent that targets an interleukin-2 receptor (IL-2R).

1
1 2. The therapeutic composition of claim 1, wherein the first agent comprises a
2 substantially pure mutant IL-15 polypeptide that binds a subunit of an IL-15R.

1
1 3. The therapeutic composition of claim 2, wherein the subunit is an IL-15R α subunit.

1
1 4. The therapeutic composition of claim 3, wherein the mutant IL-15 polypeptide has
2 a mutation at position 156 of SEQ ID NO:2.

1
1 5. The therapeutic composition of claim 4, wherein the mutant IL-15 polypeptide also
2 has a mutation at position 149 of SEQ ID NO:2.

1
1 6. The therapeutic composition of claim 4, wherein the mutation at position 156 of
2 SEQ ID NO:2 is a substitution of aspartate for glutamine.

1
1 7. The therapeutic composition of claim 5, wherein the mutation at position 149 of
2 SEQ ID NO:2 is a substitution of aspartate for glutamine.

1
1 8. The therapeutic composition of claim 5 wherein the mutant IL-15 polypeptide has a
2 substitution of aspartate for glutamine at positions 149 and 156 of SEQ ID NO:2.

1
1 9. The therapeutic composition of claim 2, wherein the first agent further comprises a
2 moiety that leads to the elimination of IL-15R-bearing cells.

1
1 10. The therapeutic composition of claim 9, wherein the moiety that lyses IL-15R-
2 bearing cells is an Fc region of an IgG molecule.

1 11. The therapeutic composition of claim 1, wherein the first agent comprises a
2 substantially pure anti-IL15R antibody.

1 12. The therapeutic composition of claim 1, wherein the second agent comprises an
2 antibody that specifically binds IL-2 or an IL-2R.

1 13. A method of suppressing an immune response in a patient, the method
2 comprising administering to the patient a therapeutic composition comprising a first
3 agent that targets an IL-15R and a second agent that targets an IL-2R.

4
5 14. The method of claim 13, wherein the patient has an immune disease,
6 particularly autoimmune disease or is at risk of developing an immune disease,
7 particularly autoimmune disease.

1
1 15. The method of claim 14, wherein the autoimmune disease is a rheumatic disease
2 selected from the group consisting of systemic lupus erythematosus, Sjögren's
3 syndrome, scleroderma, mixed connective tissue disease, dermatomyositis,
4 polymyositis, Reiter's syndrome, and Behcet's disease.

1 16. The method of claim 14, wherein the autoimmune disease is rheumatoid arthritis.

1 17. The method of claim 14, wherein the autoimmune disease is type I diabetes.

1 18. The method of claim 14, wherein the autoimmune disease is an autoimmune
2 disease of the thyroid selected from the group consisting of Hashimoto's thyroiditis
3 and Graves' Disease.

1 19. The method of claim 14, wherein the autoimmune disease is an autoimmune
2 disease of the central nervous system selected from the group consisting of multiple
3 sclerosis, myasthenia gravis, and encephalomyelitis.

1 20. The method of claim 14, wherein the autoimmune disease is a variety of
2 phemphigus selected from the group consisting of phemphigus vulgaris, phemphigus
3 vegetans, phemphigus foliaceus, Seneer-Usher syndrome, and Brazilian phemphigus.

1

1 21. The method of claim 14, wherein the autoimmune disease is psoriasis.

1

1 22. The method of claim 14, wherein the autoimmune disease is inflammatory bowel
2 disease.

1

1 23. The method of claim 13, wherein the patient has acquired immune deficiency
2 syndrome (AIDS).

1

1 24. The method of claim 13, wherein the patient has received a transplant of a
2 biological organ, tissue, or cell.

1

1 25. The method of claim 13, wherein the patient has a graft versus host disease.

1

26. A method of eliminating a cell that expresses a receptor for IL-15, the method comprising exposing the cell to the therapeutic composition comprising a first agent that targets an IL-15R and a second agent that targets an IL-2R.
27. The method of claim 26, wherein the cell is a cell of the immune system.
28. The cell of claim 26, wherein the cell is a malignant cell.
29. A method of diagnosing a patient as having a disease or condition that can be treated with the therapeutic composition of claim 1, the method comprising determining whether a biological sample obtained from the patient contains a cell that is bound by a polypeptide comprising IL-15 and an antigenic tag, the occurrence of binding indicating that the cell can be bound by an agent that targets an IL-15R *in vivo* and thereby inhibited from proliferating in response to wild-type IL-15 *in vivo*.
30. A pharmaceutically acceptable composition comprising two or more agents, each of which promote T cell death.
31. The pharmaceutical composition of claim 30, further comprising an agent that inhibits T cell proliferation.
32. The pharmaceutical composition of claim 31, wherein the composition comprises a lytic IL-2/Fc molecule, a mutant IL-15 molecule that antagonizes an IL-15 receptor, and rapamycin.
33. A pharmaceutically acceptable composition comprising at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation.

34. The pharmaceutical composition of claim 32, wherein the T cell death is AICD (activation induced cell death), passive cell death, ADCC (antibody dependent cell-mediated cytotoxicity) or CDC (complement directed cytotoxicity).

DNA sequence 489 b.p. atgagaatttcg ... aacacttcttga linear

11/11
 Met arg ile ser lys pro his leu arg ser ile ser ile gin cys tyr leu cys leu leu
 21/21
 91/31
 cta aac agt cat ttt cta acc gaa gcc gcc acc cat gtc ttc att ttg gcc tgc ttc agt
 leu asn ser his phe leu thr glu ala gly ile his val phe ile leu gly cys phe ser
 121/41
 151/51
 gca ggg ctt cct aaa aca gaa gcc aac tgg gtc aat gca ata agt gat ttg aaa aaa att
 ala gly leu pro lys thr glu ala asn trp val asn val ile ser asp leu lys lys ile
 181/61
 211/71
 gaa gat ttt att caa tct atg cat att gat gcc act tta tat acg gaa agt gat gcc cac
 glu asp leu ile gin ser met his ile asp ala thr leu tyr thr glu ser asp val his
 241/81
 271/91
 ccc agt tgc aaa gca aca gca atg aag tgc ttt ctc ttg gag tta caa gcc att tca ctt
 pro ser cys lys val thr ala met lys cys phe leu leu glu leu gin val ile ser leu
 301/101
 331/111
 gag tcc gga gat gca agt acc cat gat aca gca gaa aac ctg atc atc cta gca aac aac
 glu ser gly asp ala ser ile his asp thr val glu asn leu ile ile leu ala asn asn
 361/121
 391/131
 agt ttg tct tct aat ggg aac cca aca gaa tct gga tgc aaa gaa tgt gag gaa ctg gag
 ser leu ser ser asn gly asn val thr glu ser gly cys lys glu cys glu glu leu glu
 421/141
 451/151
 gaa aaa aat att aaa gaa ttt ttg gac agt ttt gta cat att gtc gac atg ttc atc aac
 glu lys asn ile lys glu phe leu asp ser phe val his ile val asp met phe ile asn
 481/161
 att tct tga (SEQ ID NO:1)
 thr ser opa (SEQ ID NO:2)

Fig. 1

DNA sequence 489 b.p. atgagaatttcg ... aacacttcttga linear

1/1 31/11
 atg aga att tgg aaa cca cat tgg aag agc att tcc atc cag tgc tac ttg tgc cta ctt
 Met arg ile ser lys pro his leu arg ser ile ser ile gln cys tyr leu cys leu leu
 61/21 31/31
 cta aac agt cat ttt cta act gaa gcc ggc att cat ggc ttc att ttg ggc ttt ttc agc
 leu asn ser his phe leu thr glu ala gly ile his val phe ile leu gly cys phe ser
 121/41 151/51
 gca ggg ctt ctt aaa aca gaa gcc aac tgg gtg aac gta ata agt gat ttg aaa aaa att
 ala gly leu pro lys thr glu ala asn trp val asn val ile ser asp leu lys lys ile
 181/61 211/71
 gaa gat ctt att caa tct atg cat att gat gcc att tta tat acg gaa agt gat gtt cac
 glu asp leu ile gln ser met his ile asp ala thr leu tyr thr glu ser asp val his
 241/81 271/91
 ccc agt tgc aaa gta aca gca atg aag tgc ttt ctc ttg gag tta caa gtt att tca ctt
 pro ser cys lys val thr ala met lys cys phe leu leu glu leu gln val ile ser leu
 301/101 331/111
 gag tcc gga gat gca agt att cat gat aca gta gaa aat ttg acc acc cta gca aac aac
 glu ser gly asp ala ser ile his asp thr val glu asn leu ile ile leu ala asn asn
 361/121 391/131
 agt ttg tct tct aat ggg aat gta aca gaa tct gga tgc aaa gaa tgc gag gaa ctg gag
 ser leu ser ser asn gly asn val thr glu ser gly cys lys glu cys glu glu leu glu
 421/141 451/151
 gaa aaa aat att aaa gaa ttt ttg cag agt ttt gta cat att gtc caa atg ttc atc aac
 glu lys asn ile lys glu phe leu gln ser phe val his ile val gln met phe ile asn
 481/161
 att tct tga (SEQ ID NO:3)
 thr ser opa (SEQ ID NO:4)

Fig. 2




Fig. 3A




Fig. 3B




Fig 3C




Fig. 3D




Fig. 4A




Fig. 4B




Fig. 4c




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D




Fig. 5E




Fig. 6




Fig. 7






Fig. 8

**CD4+
anti-CD25**


No-treatment



Rap



IL-2/Fc



Rap+ IL-2/Fc




Fig. 9




Fig. 10

Treatment	1° Allograft Function	MST of Functioning Grafts	n
no-Treatment	40%	6	7
Rapamycin*	50%	12	6
MR1+CTLA4/Fc+ Rapamycin**	75%	30	4
Lytic IL-2/Fc+mIL-15/Fc+ Rapamycin***	100%	>110	5
Non-lytic IL-2/Fc+mIL-15/Fc 50% +Rapamycin***		16	4

* Rapamycin treatment was initiated 7 day prior to transplantation with 3 mg/kg i.p. daily for 7 days and continued every other day for 4 wks. . DBA2 mice were used as islet allograft donors.

** MR1 treatment was administered on day -7, -5, -3, 0 to transplantation at a dose of 0.25 mg i.p. . CTLA4/Fc treatment was administered on day -7, -5, -3, 0 to transplantation at a dose of 0.2 mg i.p. .

*** IL-2/Fc, and mutant IL-15/Fc treatment was initiated 7 day prior to transplantation for 4 weeks. IL-2/Fc and mutant IL-15/Fc treatment was given at a dose of 5 µg i.p. daily for 4 weeks.

Fig. 11

Treatment	MST of Functioning Grafts	n
no-Treatment	15	4
Rapamycin*	17	4
Rapamycin + MR1+CTLA4/Fc**	25	4
Rapamycin + Lytic IL-2/Fc ***	22	4
Rapamycin + Lytic mutant IL-15/Fc ***	18	3
Rapamycin + Lytic IL-2/Fc+ mutant IL-15/Fc ***	>60	6

* Rapamycin treatment was initiated at the day of transplantation with 3 mg/kg i.p daily for 7 days and continued every other day for 4 wks. DBA2 mice were used as skin allograft donors.

** MR1 treatment was administered on day 0, 2, 4, 6 to transplantation at a dose of 0.25 mg i.p. . CTLA4/Fc treatment was administered on day 0, 2, 4, 6 to transplantation at a dose of 0.2 mg i.p. .

*** IL-2/Fc, and mutant IL-15/Fc treatment was initiated on the day of transplantation with a dose of at 5 µg i.p. daily for 4 weeks.

Fig. 12




Fig. 13

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)


PCT

(10) International Publication Number
WO 02/022805 A3

- (51) International Patent Classification⁷: C07K 14/54, 14/55, 14/715, C12N 15/62, C07K 19/00, 16/24, 16/28, A61K 38/20, 39/395, A61P 37/06
- (21) International Application Number: PCT/US01/28612
- (22) International Filing Date:
14 September 2001 (14.09.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/232,251 14 September 2000 (14.09.2000) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/232,251 (CON)
Filed on 14 September 2000 (14.09.2000)
- (71) Applicant (for all designated States except US): BETH ISRAEL DEACONESS MEDICAL CENTER, INC. [US/US]; One Deaconess Road, Boston, MA 02115 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): LI, Xian, Chang [—/US]; 17 Hemlock Road, Newton, MA 02215 (US). STROM, Terry [US/US]; 22 Kennard Road, Brookline, MA 02445 (US). ZHENG, Xin, Xiao [CN/US]; 59 Alton Place, Unit 6, Brookline, MA 02446 (US).
- (74) Agents: FREEMAN, John, W. et al.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,

[Continued on next page]

(54) Title: MODULATION OF IL-2- AND IL-15-MEDIATED T CELL RESPONSES



(57) Abstract: The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells *in vivo*. In one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that, when administered to a patient (or to a transplant *ex vivo*, reduce the number of antigen-reactive T cells. For example, the invention features compositions (e.g., pharmaceutically acceptable compositions) that include two or more agents, each of which promote T cell death. Alternatively, the composition can contain at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation. The agent that promotes T cell death can promote AICD (activation induced cell death), passive cell death, ADCC (antibody dependent cell-mediated cytotoxicity) or CDC (complement directed cytotoxicity).

WO 02/022805 A3



CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
17 July 2003

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/28612

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/54 C07K14/55 C07K14/715 C12N15/62 C07K19/00
C07K16/24 C07K16/28 A61K38/20 A61K39/395 A61P37/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, PAJ, WPI Data, EMBASE, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YON SU KIM ET AL: "Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcγ2a protein blocks delayed-type hypersensitivity" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 160, no. 12, 15 June 1998 (1998-06-15), pages 5742-5748, XP002185136 ISSN: 0022-1767 the whole document --/--	1-29



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

12 February 2003

Date of mailing of the international search report

28/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Madruga, -J

INTERNATIONAL SEARCH REPORT

Int onal Application No

PCT/US 01/28612

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BULFONE-PAUS SILVIA ET AL: "Differential regulation of human T lymphoblast functions by IL-2 and IL-15." CYTOKINE, vol. 9, no. 7, 1997, pages 507-513, XP002230804 ISSN: 1043-4666	1-3, 26, 27, 29
Y	page 510, right-hand column, paragraph 2 -page 511, right-hand column, paragraph 3; figures 1, 3	4-25, 28
Y	WO 97 41232 A (BETH ISRAEL HOSPITAL) 6 November 1997 (1997-11-06) SEQ ID NO: 6, SEQ ID NO: 7 page 47, paragraph 1 -page 53, paragraph 1; claims; figures 8, 10, 15 page 15, paragraph 2 -page 20, paragraph 2 page 43	4-25, 28, 32, 34
Y	ZHENG X X ET AL: "IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 OCT 1999, vol. 163, no. 7, 1 October 1999 (1999-10-01), pages 4041-4048, XP002230805 ISSN: 0022-1767 cited in the application the whole document	32, 34
X	TINUBU S A ET AL: "HUMANIZED ANTIBODY DIRECTED TO THE IL-2 RECEPTOR BETA-CHAIN PROLONGS PRIMATE CARDIAC ALLOGRAFT SURVIVAL" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 153, 1994, pages 4330-4338, XP002004292 ISSN: 0022-1767 the whole document	1, 12-25
X	WALDMANN T A ET AL: "The use of antibodies against the IL-2 receptor in transplantation" CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 10, no. 5, October 1998 (1998-10), pages 507-512, XP004327272 ISSN: 0952-7915 page 509, left-hand column, paragraph 4 -page 510, right-hand column, paragraph 3	1, 12-25
	-/-	

INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/US 01/28612

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 36768 A (VLAAMS INTERUNIV INST BIOTECH ;DOOMS HANS PETER RAF. (BE); FIER WA) 27 August 1998 (1998-08-27) claims; examples	1-29,32, 34
X	GUEx-CROSIER Y ET AL: "Humanized anti-IL-2 and anti-IL-15 receptor antibodies in the treatment of uveoretinitis in a monkey model." INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 37, no. 3, 1996, page S896 XP008013716 1996 Annual Meeting of the Association for Research in Vision and Ophthalmology;Fort Lauderdale, Florida, USA; April 21-26, 1996 ISSN: 0146-0404 the whole document	1,11-14
A	KIM Y S ET AL: "IMMUNOGLOBULIN-CYTOKINE FUSION MOLECULES: THE NEW GENERATION OF IMMUNOMODULATING AGENTS" TRANSPANTATION PROCEEDINGS, ORLANDO, FL, US, vol. 30, no. 8, 1998, pages 4031-4036, XP001031432 ISSN: 0041-1345 page 4035, right-hand column, paragraph 2; table 4	1-29,32, 34
A	RUECKERT RENE ET AL: "IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both." EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 28, no. 10, October 1998 (1998-10), pages 3312-3320, XP002230807 ISSN: 0014-2980 the whole document	1-29,32, 34

INTERNATIONAL SEARCH REPORT

ational application No.
PCT/US 01/28612**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 13-28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 30, 31, 33
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 30,31,33

Present claims 30, 31 and 33 relate to a composition defined by reference to a desirable characteristic or property, namely its ability to promote T cell death and/or inhibit T cell proliferation.

The claims cover all compositions having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compositions. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the composition by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, no search has been carried out for those claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/28612

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9741232	A	06-11-1997	CA 2252557 A1 06-11-1997
		EP 0927254 A1 07-07-1999	
		JP 2001502521 T 27-02-2001	
		WO 9741232 A1 06-11-1997	
		US 6451308 B1 17-09-2002	
		US 6001973 A 14-12-1999	
WO 9836768	A	27-08-1998	AT 229342 T 15-12-2002
		AU 6726698 A 09-09-1998	
		DE 69810091 D1 23-01-2003	
		WO 9836768 A1 27-08-1998	
		EP 1273304 A2 08-01-2003	
		EP 0971728 A1 19-01-2000	
		US 2002182178 A1 05-12-2002	
		US 6344192 B1 05-02-2002	
		ZA 9801478 A 24-08-1998	

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035105 A2

(51) International Patent Classification⁷: **A61K 39/39**

(21) International Application Number: **PCT/CA02/01649**

(22) International Filing Date: **23 October 2002 (23.10.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/330,476 23 October 2001 (23.10.2001) US

(71) Applicant (for all designated States except US): **CENTRE FOR TRANSLATIONAL RESEARCH IN CANCER [CA/CA]; 3755 chemin de la Côte Ste-Catherine, Montréal, Québec H3T 1E2 (CA).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GALISPEAU, Jacques [CA/CA]; 251, Morrison, Town of Mount-Royal, Québec H3R 1K7 (CA). STAGG, John [CA/CA]; 5245 Côte Ste-Catherine, Apt. 14, Montréal, Québec H3W 1M9 (CA).**

(74) Agent: **OGILVY RENAULT; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).**

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/035105 A2

(54) Title: **A NOVEL SYNTHETIC CHIMERIC FUSION TRANSGENE WITH IMMUNO-THERAPEUTIC USES**

(57) Abstract: The present invention relates to an immuno-therapy conjugate which comprises A-c-B wherein: A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues. The present invention also relates to a vaccine adjuvant comprising the immuno-therapy conjugate of the present invention. The present invention further relates to a method of reducing tumor growth, for inhibiting a viral infection and for improving immune response in a patient.

**A NOVEL SYNTHETIC CHIMERIC FUSION TRANSGENE WITH
IMMUNO-THERAPEUTIC USES**

BACKGROUND OF THE INVENTION

5 (a) Field of the Invention

The invention relates to a novel synthetic chimeric fusion gene and protein with immuno-therapeutic uses.

(b) Description of Prior Art

10 Research focusing on immunomodulation is attracting growing interest. DNA vaccines encoding for antigenic peptides have recently been developed as a novel vaccination technology against viral infections such as HIV (Ahlers JD. *et al.*, *Proceedings of the National Academy of Sciences of the United States of America*. 94(20):10856-61, 1997 Sep 30.), as well as against cancer (Strominger JL., *Nature Medicine*. 15 1(11):1140, 1995 Nov). For these next generation of vaccines based on poorly immunogenic antigens, there is a great need for powerful adjuvants, both strong and safe, that can be used to enhance the immune response. Although many adjuvants such as LPS, LT and CT are used experimentally today (Vogel FR. Powell MF., [Review]. *Pharmaceutical* 20 *Biotechnology*. 6:141-228, 1995), most of them comprise a toxic fragment that is required for adjuvanticity, thus greatly hampering their clinical use.

The delivery of cytokine genes to enhance immune response to synthetic peptide vaccines may therefore represent an advantage over conventional adjuvants. Vaccination studies with genetically engineered 25 cancer cells secreting cytokines such as IL-4, IL-6, IL-7, INF- γ , TNF- α , IL-12, GM-CSF or IL-2 (Dranoff G. *et al.*, *Proceedings of the National Academy of Sciences of the United States of America*. 90(8):3539-43, 1993 Apr 15) (Irvine KR. *et al.*, *Journal of Immunology*. 156(1):238-45, 1996 Jan 1) have been shown to generate tumor-specific immune 30 responses. Several studies have shown in addition that co-expressing some of these cytokines generated synergistic antitumor effects. Comparing the adjuvant effects of several cytokines on DNA vaccines revealed that the co-expression of GM-CSF and IL-2 genes induced the higher antibody titers and T cell proliferation response than other cytokine

genes tested to date (Pan CH. *et al.*, [Review] *Journal of the Formosan Medical Association*. 98(11):722-9, 1999 Nov). The co-expression of GM-CSF and IL-2 by tumor cells was also shown to induce potent synergistic antitumor effect (Lee SG. *et al.*, *Anticancer Research*. 20(4):2681-6, 2000 Jul-Aug).

A bifunctional chimeric gene product borne from the fusion of GM-CSF and IL-2 cDNA may therefore display novel and potent immunostimulatory properties that could supersede that seen with either protein alone or expressed in combination. Granted, such a fusion sequence would be bereft of a true physiological role. However, the aim of cancer immunotherapy is to elicit as violent an immune reaction as possible against tumor. The idea of fusing GM-CSF with an interleukin is viable. As an example, the proprietary PIXY321 recombinant protein marketed by Immunex® is a fusion of GM-CSF and IL-3 (Curtis BM. *et al.*, *Proceedings of the National Academy of Sciences of the United States of America*. 88(13):5809-13, 1991 Jul 1). This molecule was marketed as a stimulator of hematopoietic recovery from chemotherapy toxicity. Its successful bioengineering demonstrates the feasibility of fusing GM-CSF with interleukins.

GM-CSF was first described as a growth factor for granulocyte and macrophage progenitor cells. However, GM-CSF is also an important mediator for inflammatory reactions produced by T lymphocytes, macrophages and mast cells present at sites of inflammation (reviewed in Demetri GD. Griffin JD., [Review] *Blood*. 78(11):2791-808, 1991 Dec 1). GM-CSF is a strong chemoattractant for neutrophils. It enhances microbicidal activity, phagocytotic activity and cytotoxicity of neutrophils and macrophages. An important feature of GM-CSF is that it greatly enhances the state of antigen presentation on dendritic cells, known to be crucial mediators of acquired immunity.

IL-2 on the other hand is an essential cytokine for the expansion of activated lymphocytes. IL-2 also supports the functional differentiation of mature lymphocytes, including CTL, NK cells and B cells. Moreover, IL-2 enhances CTL activity in activated primary CD8⁺ T cells through the fact that IL-2 upregulates mRNA for FasL, perforin and granzyme B, all of

which are involved in the mechanism of CTL killing (Makrigiannis AP, Hoskin DW., *Journal of Immunology*. 159(10):4700-7, 1997 Nov 15). NK cells also proliferate and upregulate their cytolytic activity in response to IL-2, but require relatively high doses of IL-2 since they do not express the high affinity receptor complex.

It would be highly desirable to be provided with a novel synthetic chimeric fusion transgene and protein with immuno-therapeutic uses.

SUMMARY OF THE INVENTION

It is reported herein the successful engineering of a DNA plasmid encoding for a novel chimeric protein borne from the fusion of murine GM-CSF and murine IL-2 cDNA. The fusion was generated by restriction enzyme cloning, and resulted in a truncated murine GM-CSF cDNA at the 5' end linked by a 3-bp linker to a the full length murine IL-2 cDNA at the 3' end. Moreover, the expression of this fusion sequence in B16 murine melanoma cells led to the secretion of a GMCSF/IL2 fusion protein that greatly reduced the tumorigenicity of the cells in a syngeneic mouse model.

The novel immunostimulatory properties of this fusion transgene lead to an anti-cancer therapeutic effect. The present application shown that the nucleotide sequence encoding for GIFT can be utilized as a therapeutic transgene for gene therapy of cancer. The present application proposes that the fusion transgene nucleotide sequence can be utilized for: (i) genesis of cell and gene therapy biopharmaceuticals for treatment of cancer, (ii) as a genetic immunoadjuvant to DNA vaccine technologies for use in the prevention and treatment of cancer or infectious diseases in humans and other mammals and, (iii) as a genetic immunoadjuvant for production of commercially valuable monoclonal and polyclonal antibodies in mammals.

In accordance with the present invention there is provided an immuno-therapy conjugate which comprises:

A-c-B

wherein:

A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and

5 c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues.

The conjugate in accordance with a preferred embodiment of the present invention, wherein the cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11,
10 IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

The conjugate in accordance with a preferred embodiment of the present invention, wherein the chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7,
15 CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

20 The conjugate in accordance with a preferred embodiment of the present invention, wherein the interferon is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

25 In accordance with the present invention, there is provided an immuno-therapy fusion cDNA encoding the immuno-therapy conjugate of the present invention.

In accordance with the present invention, there is provided a vaccine adjuvant for DNA vaccination which comprises the conjugate of the present invention.

30 The vaccine adjuvant in accordance with a preferred embodiment of the present invention, wherein the vaccination is against an infectious organism.

The vaccine adjuvant in accordance with a preferred embodiment of the present invention, wherein the infectious organism is selected from the group consisting of: viruses, bacteries, mycobacteria, protozoa and prions.

- 5 The vaccine adjuvant in accordance with a preferred embodiment of the present invention, wherein the virus is selected from the group of Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Apthovirus and Filovirus.

- 10 The vaccine adjuvant in accordance with a preferred embodiment of the present invention, wherein the vaccination is against malignancies, wherein the malignancies having at least one immunogen associated thereto.

- 15 In accordance with the present invention, there is provided a vaccine adjuvant for vaccination, which comprises the fusion cDNA of the present invention.

In accordance with the present invention, there is provided a method for reducing tumor growth in a patient, the method comprising administering to the patient a therapeutically effective amount of the conjugate of the present invention.

- 20 In accordance with the present invention, there is provided a method for reducing tumor growth in a patient, the method comprising administering to the patient a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of the present invention.

- 25 In accordance with the present invention, there is provided a method for inhibiting a viral infection in a patient, the method comprising administering to the patient a therapeutically effective amount of the conjugate of the present invention.

- 30 In accordance with the present invention, there is provided a method to inhibit a viral infection in a patient, the method comprising administering to the patient a therapeutically effective amount of the fusion cDNA of the present invention using a gene delivery technique.

The method in accordance with a preferred embodiment of the present invention, wherein the gene delivery technique is selected from the group consisting of: recombinant viral based vectors and plasmid DNA delivery methods.

5 In accordance with the present invention, there is provided a method to inhibit a viral infection in a patient, the method comprising administering to the patient a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of the present invention.

10 In accordance with the present invention, there is provided a method to allow production of antigen-specific antibodies, the method comprising the administration of the species-specific fusion cDNA of claim 5 with the cDNA of the antigen or functional fragment thereof in experimental mammals.

15 In accordance with the present invention, there is provided a method to inhibit a viral infection in a patient, the method comprising administering to the patient a therapeutically effective amount of the fusion cDNA of the present invention using a gene delivery technique.

20 In accordance with the present invention, there is provided the use of a therapeutically effective amount of the conjugate of the present invention for reducing tumor growth in a patient.

 In accordance with the present invention, there is provided the use of a therapeutically effective amount of the fusion cDNA of the present invention with a gene delivery technique for reducing tumor growth in a
25 patient.

 In accordance with the present invention, there is provided the use of a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of the present invention for reducing tumor growth in a patient.

30 In accordance with the present invention, there is provided the use of a therapeutically effective amount of the conjugate of the present invention for inhibiting a viral infection in a patient.

 In accordance with the present invention, there is provided the use of a therapeutically effective amount of the fusion cDNA of the present

invention with a gene delivery technique to inhibit a viral infection in a patient.

In accordance with the present invention, there is provided the use of a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of the present invention to inhibit a viral infection in a patient.

In accordance with the present invention, there is provided the use of species-specific fusion cDNA of the present invention with the cDNA of antigen or functional fragment thereof to allow production of antigen-specific antibodies in mammals.

In accordance with the present invention, there is provided the use of a therapeutically effective amount of the conjugate of the present invention to improve immune response in a patient.

For the purpose of the present invention the following terms are defined below.

The term "subject" is intended to mean humans, mammals and/or vertebrates.

The term "functional fragment" is intended to mean a fragment that as conserved the same activity as the entire product.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates pGMCSF and pIL2 restriction enzyme maps;

Fig. 2 illustrates pGMCSF *EcoRI* digest on agarose gel;

Fig. 3 illustrates pGMCSF *EcoRV* digest on agarose gel, after *EcoRI* digestion;

Fig. 4 illustrates pIL2 *PstI* digest;

Fig. 5 illustrates pIL2 *EcoRI* digest (after *PstI* and S1 nuclease);

Fig. 6 illustrates the ligation of mGM-CSF to mL-2;

Fig. 7 illustrates the ligation product *HindIII* digest;

Fig. 8 illustrates pJS330 confirmation digest;

Fig. 9 illustrates pJS330 restriction map;

Fig. 10 illustrates the amino acid sequence of a schematic fusion protein showing the positive sequencing of the fusion between mouse GM-CSF cDNA and mouse IL-2 cDNA;

5 Fig. 11 illustrates pJS330 *XhoI-HpaI* digest and AP2 *BamHI* digest;

Fig. 12 illustrates pJS4 confirmation digest;

Fig. 13 illustrates pJS4 restriction map;

Fig. 14 illustrates the secretion of the fusion protein by the JS4-transduced B16 cells;

10 Fig. 15 illustrates immunoblotting of the fusion protein with monoclonal antibodies against mouse IL-2 or mouse GM-CSF;

Fig. 16 illustrates the antitumor effect of the mGM-CSF/mIL2 fusion sequence when expressed in B16 melanoma cells;

15 Fig. 17 illustrates H&E staining of 5 μ m tumor sections from mice injected s.c. with 10^6 B16 cells engineered to secrete the mGMGSF/mIL2 fusion protein and GFP (Figs. 17B and 17D) or engineered to secrete GFP only (Figs. 17A and 17C); and

Fig. 18 illustrates the level of secretion of the fusion protein determined *in vitro* by ELISA.

20 DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided a novel synthetic chimeric fusion transgene with immuno-therapeutic uses. It is therefore proposed that a bifunctional chimeric gene product borne from the fusion of GM-CSF and IL-2 cDNA may display novel and potent
25 immunostimulatory properties that could supersede that seen with either protein alone or expressed in combination. Further, a fusion transgene will guarantee equimolar production of GM-CSF and IL-2 by all engineered cells. This is of significance, since independent transfer of IL-2 and GM-CSF is random in distribution, and it is only by chance that any
30 gene-transfected cell express both protein.

Materials and methods

Mouse IL2 and mouse GM-CSF cDNAs were purchased from the National Gene Vector Laboratories (NGVL, The University of Michigan). The synthesis of the fusion protein expression plasmid, namely pJS330, was as follow.

Cloning pIL2

The 557-bp IL2 cDNA was excised by *Pst1-Swa1* restriction digest and ligated to the 3970-bp pEGFP-N1 (Clontech, Palo Alto, CA) fragment generated with *Not1*, Klenow fill-in and *Pst1*. This murine IL2 expression plasmid is referred to as pIL2 in the following text.

Cloning pGMCSF

The 462-bp GM-CSF cDNA was excised by *Sal1-BamH1* restriction digest and ligated into the previously reported plasmid AP2 after *Xho1-BamH1* digest. Briefly, AP2 is a plasmid encoding for a bicistronic murine retrovector that incorporates a multiple cloning site, allowing insertion of a cDNA of interest. This murine GM-CSF expression plasmid is referred to as pGMCSF in the following text.

Cloning pJS330

A 398-bp fragment from pGMCSF containing the cDNA for the mouse GM-CSF (truncated 33-bp prior to the stop codon) was excised by *EcoRI* followed by *EcoRV*. This truncated cDNA was ligated to the 5' end of the mIL2 gene into pIL2. Prior to ligation, pIL2 was digested with *Pst1* (cutting 3-bp prior to IL2 start codon), followed by S1 nuclease to remove single stranded DNA, and *EcoR1* digest. 30µl of the 398-bp of pGMCSF was added to 55µl of the 4518-bp of pIL2 in the presence of DNA ligase for 16 hours at 14°C. Transformation of the ligation product was carried on in DH5α competent bacteria, and the bacteria subsequently were plated on agar. Colonies were grown for 12 hours and individual clones were picked and grew in LB broth for 12 hours. The DNA was then isolated using a commercial kit. The ligation product is referred to as pJS330 in the following text and encodes the fusion protein mGM-CSF/mIL2.

The fusion mGM-CSF/mIL2 DNA coding sequence within pJS330 was subsequently sent for sequencing at the Guelph Molecular Supercentre (University of Guelph, Ontario). The two sequencing primers used (i.e. 5'-ACAGCCAGCTACTACCAGAC-3' [P1] (SEQ ID NO:1) and 5'-CGCTACCGGACTCAGATCTC-3' [P2] (SEQ ID NO:2)) were generated at the Sheldon Biotechnology Center (McGill University, Montreal).

Cloning pJS4

A 1090-bp fragment from pJS330 containing the fusion protein coding sequence was excised by *XhoI-HpaI* restriction digest and ligated into AP2 after *BamHI*, Klenow fill-in and *XhoI*. The ligation product is a retrovector plasmid referred to as pJS4 that allows for the expression of mGM-CSF/mIL2 fusion protein and GFP, as well as the generation of retrovectors when transfected into packaging cell lines.

Fusion Protein Expression

The expression and secretion of the mGM-CSF/mIL2 fusion protein was confirmed by ELISA. 5µg of the retrovector plasmid pJS4 or AP2 were digested with *PstI* and co-transfected with 0.5µg of pJ6ΩBleo plasmid into GP+E86 retrovector packaging cells (American Type Culture Collection [ATCC]) with the use of Lipofectamine™ (Life Technologies, Inc.). Transfected cells were subsequently selected in DMEM media (10% heat-inactivated FBS plus 50 units/ml of Pen-Strep™) supplemented with 100µg/ml Zeocin™ (Invitrogen, San Diego, CA) for 4 weeks. Resulting stable producers generated ecotropic retroviral titers of 10⁵ cfu/ml. GP+AM12 retrovector packaging cells (ATCC) were transduced with 10ml of fresh supernatant from pJS4 or AP2-transfected GP+E86 (plus 6µg/ml Lipofectamine) twice daily for 3 consecutive days. Resulting stable producers generated amphotropic viral titers of 10⁵ cfu/ml. B16 murine melanoma cells were transduced with 10ml of fresh supernatant from pJS4 or AP2-transduced GP+AM12 (plus 6µg/ml Lipofectamine) twice daily for 6 consecutive days. One week later, 24 hours old supernatant was collected from B16-transduced cells, namely B16-JS4 and B16-AP2, and the cells counted by hemacytometer. The collected supernatant was frozen until thawed for ELISA detecting the presence of mGM-CSF protein (Biosource, San Diego, CA) or mIL-2 protein

(Biosource, San Diego, CA) in the supernatant according to the manufacturer's instructions.

B16 modified cells *in vivo* implantation

5 Murine B16 engineered melanoma cells secreting the fusion protein and the reporter GFP (B16-JS4 cells) were injected subcutaneously (s.c.) in syngenic immunocompetent C57bl/6 mice. As a control, B16 melanoma cells expressing GFP only (B16-AP2 cells) were injected. Prior to implantation, the cells were trypsinized and centrifuged at 2000 rpm for 5 minutes in the presence of 10% FBS DMEM media.

10 The cells were then resuspended in PBS. One million cells (in 100 μ l PBS) were injected per mouse using a 25^{5/8} gauge syringe. Seven mice per group were injected subcutaneously and tumor volume was measured over time with a vernier caliper using the following formula: tumor volume = tumor length x (tumor width)² / 2.

15 Histology

Control tumors were resected at day 20 post-implantation while tumors expressing the fusion protein were resected at day 52 post-implantation. Resected tumors were immediately fixed in 10% formalin, and subsequently embedded in paraffin, cut in 5 μ m-thick sections and

20 stained with hematoxylin and eosin (H&E). Four sections per tumor were blindly examined microscopically by a pathologist to characterize the immune infiltration.

Results

The cDNA for mouse GM-CSF and mouse IL2 were purchased

25 from the National Gene Vector Laboratories and subsequently subcloned in two distinct expression plasmids, namely pGMCSF and pIL2 (Fig. 1). pGMCSF expression plasmid was first digested with *EcoRI* restriction enzyme and a sample run on agarose gel for confirmation (Fig. 2). In Fig. 2, column A is 1kb DNA ladder, column B is uncut pGMCSF, column C is

30 52 bp, 453bp, 2321 bp and 4265 bp fragments of pGMCSF *EcoRI* (Eth.Br. agarose gel 0.8%). The remaining DNA was then digested with *EcoRV* (Fig. 3) and the 398-bp band containing the mGM-CSF sequence was excised and purified. In Fig. 3, column A is 1 kb DNA ladder, column B is

uncut pGMCSF, column C is 398bp, 878bp, 1443bp and 4265bp fragments of pGMCSF. Meanwhile, the pIL2 expression plasmid was linearized with *Pst*I and a sample was run on agarose gel for confirmation (Fig. 4). In Fig. 4, column A is 1kb DNA ladder, column B is uncut pIL2 and column C is linear pIL2 after *Pst*I. The remaining DNA was then deprived from any single-chain overhangs using S1 nuclease. Subsequently, the DNA was digested with *Eco*RI and the 4518-bp band containing the mIL2 cDNA sequence was excised and purified (Fig. 5). In Fig. 5, column A is 1kb DNA and column B is pIL2 4518bp Band (Eth. Br. agarose gel 0.8%). 5µl of the 398-bp DNA and 5µl of the 4518-bp DNA were run in parallel on agarose gel prior to ligation (Fig. 6). In Fig. 6, column A is 1kb DNA ladder, column B is 4518bp band of pIL2 and column C is 398bp band of pGMCSF (Eth.Br. agarose gel 0.8%). Following transformation of the ligation product in competent AH5α bacteria, 40 individual clones were screened for the presence of the fusion sequence plasmid. The collected DNA was digested with *Hind*III for a first screen of a potential clone encoding the correct fusion sequence (Fig. 7). In Fig. 7, column A is 1kb DNA ladder, columns B to L are clones 21 to 31 respectively. Expected bands for pJS330 are 738bp and 4178bp (Eth.Br. agarose gel 0.8%). Clone number 30 was identified as positive, and further used for confirmation with *Sac*I (Fig. 8). In Fig. 8, column A is 1kb DNA ladder, column B is pJS330 uncut, column C is pIL2 uncut, column D is pJS330 *Hind*III digest (expected bands 583bp and 4333bp), column F is pIL2 *Hind*III and G is pIL2 *Sac*I. (Eth.Br. agarose gel 0.8%). Fig. 9 is a restriction enzyme map of the plasmid pJS330 showing the sites used for confirmation.

The DNA of clone number 30, namely pJS330, that showed to be positive by restriction enzymes for the presence of the fusion gene, was sent for sequencing using two distinct primers. Sequencing primer 1 (P1) is complementary to a 20-bp sequence 5' of the expected glycine linker between mGM-CSF and mIL2. Sequencing primer 2 (P2) is complementary to a 20-bp sequence 5' of the start codon of mGM-CSF. Figure 10 represents the complete sequence analysis of the novel synthetic fusion transgene. In figure 10, A is the sequence analysis

obtained from P1, B is the sequence analysis obtained from P2, and C is a schematic illustration of the predicted amino acid sequence.

In order to engineer cancer cells to express this fusion gene, it has been generated a retrovector plasmid that encodes the mGMCSF/mIL2 fusion and the reporter GFP. The plasmid pJS330 was digested with *XhoI*-*HpaI* and the 1090-bp band containing the fusion gene was excised and purified (Fig. 11). In Fig. 11, column A is 1kb DNA ladder, column B is pJS330 uncut, column C is 1090bp and 3826bp fragments of pJS330 *XhoI*-*HpaI*, column D is 1kb DNA ladder, column E is AP2 uncut and column F is AP2 *BamHI* (Eth. Br. Agarose gel 0.8%). AP2 was first linearized with *BamHI*, then single-chained overhangs were filled-in, and the DNA digested with *EcoRI*. The two fragments (from pJS330 and AP2) were ligated, and the ligation product (pJS4) screened with *BglII* and *XhoI*-*Apal* digests (Fig. 12). In Fig. 12, column A is 1kb DNA ladder, column B is pJS4 uncut, column C is AP2 uncut, column D is pJS4 *BglII* digest (expected bands 685bp and 7034bp), column E is AP2 *BglII* digest, column F is pJS4 *XhoI*-*Apal* digest (expected bands 1233 bp and 6486bp), column G is AP2 *XhoI*-*Apal* digest and column H is 1kb DNA ladder (Eth. Br. agarose gel 0.8%). Fig. 13 is a restriction enzyme map of the plasmid pJS4 showing the sites used for confirmation.

The retrovector plasmid pJS4 encoding the fusion sequence was transfected into GP+E86 packaging cells and the supernatant used to transduced GP+AM12 packaging cells. The supernatant of GP+AM12 was used to transduce B16 murine melanoma cells. The JS4- transduced B16 cells were assessed for secretion of the fusion protein by ELISA. The supernatant from B16-JS4 cells was positive for GM-CSF and IL-2 by ELISA confirming the secretion of the fusion protein (Fig. 14). In Fig. 14, A is the concentration of IL-2 produced by B16-JS4 cells, B is the concentration of IL-2 produced by non-modified B16 cells, C is the concentration of GM-CSF produced by B16-JS4 cells and D is the concentration of GM-CSF produced by naïve B16 cells. The molecular weight of the fusion protein was determined to be between 43 and 48 kilo Dalton (kD) by immunoblotting with monoclonal antibodies against mouse IL-2 or mouse GM-CSF (Fig 15). In Fig. 15, A is recombinant mouse IL-2 probed against IL-2, B is recombinant mouse GM-CSF probed against IL-

2; C is the fusion protein from B16-JS4 supernatant probed against IL-2, D is recombinant mouse GM-CSF probed against GM-CSF, E is recombinant mouse IL-2 probed against GM-CSF and F is the fusion protein from B16-JS4 supernatant probed against GM-CSF.

5 In order to confirm that the fusion protein generated from the novel fusion transgene has immuno-therapeutic uses, one million polyclonal B16-JS4 cells were injected subcutaneously into C57bl/6 mice. As a control, one million B16-AP2 cells were injected in C57bl/6 mice. After 20 days, all mice injected with control B16-AP2 cells had to be
10 sacrificed because the mean tumor volume was more than 800 mm³. In contrast, none of the mice injected with B16-JS4 secreting the fusion protein had a tumor. By day 52 post-implantation, 3 out of 7 mice injected with B16-JS4 cells still did not show any palpable tumor while 4 out of 7 had a mean tumor volume of 25 mm³ (Fig. 16). In Fig. 16, B16 murine
15 melanoma cells were engineered in vitro to express the fusion sequence and GFP (B16-JS4) or to express GFP only (B16-AP2). The level of secretion of the fusion protein was determined in vitro by ELISA on the supernatant of B16-JS4 cells (4ng of GM-CSF/10⁶ cells/24h and 2ng of IL-2/10⁶ cells/24h). These tumors were then surgically removed at day
20 52, mounted on paraffin sections and stained with hematoxylin and eosin. The immune infiltration of B16-JS4 tumors was compared to the immune infiltration of B16-AP2 tumors (Fig 17). Compared to control tumors showing minimal immune infiltration (Figs 17A and 17C), tumors secreting the fusion protein were characterized by an intense intratumoral
25 suppurative inflammation (Figs 17B and 17D). The inflammation was diffuse through the tumor mass of all JS4 tumors and mainly consisted of neutrophils surrounding degenerated tumor cells.

The immuno-therapeutic effects of the novel synthetic fusion transgene were further compared to those of IL-2 or GM-CSF cDNA. The
30 retrovector plasmid pIL2 (cloned in AP2) or pGMCSF was transfected into GP+E86 packaging cells and the supernatant used to transduce GP+AM12 packaging cells. The supernatant of GP+AM12 was used to transduce B16 murine melanoma cells. Clonal populations of the B16 cells thus generated to produce IL-2 or GM-CSF, as well as clonal
35 populations of B16-JS4 cells secreting the fusion protein, were isolated.

In order to compare the immuno-therapeutic effects of the fusion protein to those of IL-2 or GM-CSF, one million clonal B16 cells secreting IL-2 (B16-IL2), GM-CSF (B16-GMCSF) or equimolar concentration of the fusion protein (B16-JS4) were injected subcutaneously into C57bl/6 mice. As a control, one million B16-AP2 cells were injected in C57bl/6 mice. At 40 days after injection, all mice injected with B16-JS4 cells secreting the fusion protein were tumor-free, while 20% of mice injected with B16-IL2 and 100% of mice injected with B16-GMCSF had developed a tumor (Fig. 18). In Fig. 18, the level of secretion of the fusion protein was determined in vitro by ELISA on the supernatant of B16-JS4 cells (8ng of GM-CSF/106 cells/24h and 4ng of IL-2/106 cells/24h).

Discussion

In the present application, it is reported the successful engineering of a DNA plasmid encoding for a chimeric protein borne from the fusion of murine GM-CSF and murine IL-2 cDNA. The fusion sequence thereby generated was confirmed by sequence analysis using two distinct DNA primers and revealed the expected presence of a single glycine linker between the 11 amino acid-truncated 3' end of GM-CSF and the first amino acid of IL-2. When this expression plasmid was transduced into B16 murine melanoma cells, a potent *in vivo* antitumor effect was observed despite normal cell growth *in vitro*. 52 days after the s.c. injection of 10^6 B16-JS4 cells, 3 out of 7 mice failed to develop any tumor. In the 4 mice that did develop cancer, the mean tumor volume was only 25mm^3 after 52 days. Histopathology of the tumors expressing the GMCSF/IL2 fusion sequence revealed an intense intratumoral immune infiltration, mainly consisting of neutrophils and other granulocytes. This suggests that the novel fusion protein is strongly chemotactic for granulocytes, most likely reflecting the GM-CSF subunit activity of the chimera. It is shown herein that the IL-2 portion of the fusion protein is responsible in part, for inhibiting tumor growth. The combined GM-CSF/IL2 have additive beneficial anti-cancer effects such as direct tumoricidal activity and immune recruitment for a "tumor vaccine" effect. It is also shown herein that the humanized version of this murine GMCSF/IL2 fusion DNA sequence will share the same characteristics in humans with cancer. Similarly, species-specific configurations of

GMCSF/IL2 fusion gene could be used for veterinary therapeutic purposes.

A second application of this transgene would be as part of a genetic immunoadjuvant of a DNA vaccine for cancer or infectious diseases such as HIV, Hepatitis C or others. Co-expression of an antigen-encoding cDNA and GMCSF/IL2 fusion nucleotide sequence will lead to antigen presentation in a milieu co-generating the GMCSF/IL2 protein, where the GMCSF/IL2 will stimulate a potent immune response (Th1 and Th2) against the presented antigen. Such chimeric cytokine gene could therefore be used as a powerful genetic non-toxic adjuvant to DNA vaccination. Therapeutic use in human clinical applications, as well as agrobusiness applications such as infectious disease of commercially valuable mammals could benefit of such a powerful immunostimulatory cDNA.

It is also proposed that either tumor-targeted delivery of the fusion cDNA (gene) or of the recombinant protein (fusion protein) will have a therapeutic anti-cancer effect in humans. Furthermore, because it has been reported that the highest antibody titers against a DNA vaccine can be obtained when combining the expression of an antigenic peptide to the expression of GM-CSF together with IL-2, the GMCSF/IL2 fusion gene serves as a genetic tool for the generation of polyclonal and monoclonal antibodies as biotechnological reagents. Its use in its current configuration, when co-expressed with a open-reading-frame (ORF) gene, allows the generation of a potent and specific anti-ORF gene product humoral immune reaction. From these immunized animals (mice, rats, goats, etc.) splenocytes could be harvested and utilized to generate novel monoclonal antibody-producing cell lines of commercial interest.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential

features hereinbefore set forth, and as follows in the scope of the appended claims.

WHAT IS CLAIMED IS:

1. An immuno-therapy conjugate which comprises:
A-c-B
wherein:
A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and
c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues.
2. The conjugate as claimed in claim 1, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.
3. The conjugate as claimed in claim 1, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.
4. The conjugate as claimed in claim 1, wherein said interferon is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.
5. An immuno-therapy fusion cDNA encoding the immuno-therapy conjugate of claim 1.

6. The fusion cDNA as claimed in claim 5, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18; or a functional fragment thereof.

7. The fusion cDNA as claimed in claim 5, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

8. The fusion cDNA as claimed in claim 5, wherein said interferon is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

9. A vaccine adjuvant for DNA vaccination which comprises the conjugate of claim 1.

10. The vaccine adjuvant as claimed in claim 9, wherein said vaccination is against an infectious organism.

11. The vaccine adjuvant as claimed in claim 10, wherein said infectious organism is selected from the group consisting of: viruses, bacteria, mycobacteria, protozoa and prions.

12. The vaccine adjuvant as claimed in claim 11, wherein said virus is selected from the group of Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

13. The vaccine adjuvant as claimed in claim 9, wherein said vaccination is against malignancies, wherein said malignancies having at least one immunogen associated thereto.
14. A vaccine adjuvant for vaccination, which comprises the fusion cDNA of claim 5.
15. The vaccine adjuvant as claimed in claim 14, wherein said vaccination is against an infectious organism.
16. The vaccine adjuvant as claimed in claim 15, wherein said infectious organism is selected from the group consisting of: viruses, bacteria, mycobacteria, protozoa and prions.
17. The vaccine adjuvant as claimed in claim 16, wherein said virus is selected from the group consisting of: Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.
18. The vaccine adjuvant as claimed in claim 14, wherein said vaccination is against malignancies, wherein said malignancies having at least one immunogen associated thereto.
19. A method for reducing tumor growth in a patient, said method comprising administering to said patient a therapeutically effective amount of the conjugate of claim 1.
20. The method as claimed in claim 19, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.
21. The method as claimed in claim 19, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4,

CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

22. The method as claimed in claim 19, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

23. A method for reducing tumor growth in a patient, said method comprising administering to said patient a therapeutically effective amount of the fusion cDNA of claim 5 using a gene delivery technique.

24. The method as claimed in claim 23, wherein said gene delivery technique is selected from the group consisting of: recombinant viral based vectors and plasmid DNA delivery methods.

25. The method as claimed in claim 23, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF; TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

26. The method as claimed in claim 23, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

27. The method as claimed in claim 23, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

28. A method for reducing tumor growth in a patient, said method comprising administering to said patient a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of claim 5.

29. The method as claimed in claim 28, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

30. The method as claimed in claim 28, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

31. The method as claimed in claim 28, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

32. A method for inhibiting a viral infection in a patient, said method comprising administering to said patient a therapeutically effective amount of the conjugate of claim 1.

33. The method of claim 32, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

34. The method as claimed in claim 32, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

35. The method as claimed in claim 32, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

36. The method as claimed in claim 32, wherein said virus is selected from the group consisting of: Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

37. A method to inhibit a viral infection in a patient, said method comprising administering to said patient a therapeutically effective amount of the fusion cDNA of claim 6 using a gene delivery technique.

38. The method as claimed in claim 37, wherein said gene delivery technique is selected from the group consisting of: recombinant viral based vectors and plasmid DNA delivery methods.

39. The method as claimed in claim 37, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α ,

Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

40. The method as claimed in claim 37, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27; or a functional fragment thereof.

41. The method as claimed in claim 37, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

42. The method as claimed in claim 37, wherein said virus is selected from the group consisting of: Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

43. A method to inhibit a viral infection in a patient, said method comprising administering to said patient a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of claim 5.

44. The method as claimed in claim 43, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

45. The method as claimed in claim 43, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

46. The method as claimed in claim 43, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

47. The method as claimed in claim 43, wherein said viral infection is selected from the group consisting of : Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

48. A method to allow production of antigen-specific antibodies, said method comprising the administration of the species-specific fusion cDNA of claim 5 with the cDNA of the said antigen or functional fragment thereof in mammals.

49. The method as claimed in claim 48, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

50. The method as claimed in claim 48, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13,

CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

51. The method as claimed in claim 48, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

52. A method to improve immune response in a patient, said method comprising administering to said patient a therapeutically effective amount of the conjugate of claim 1.

53. The method as claimed in claim 52, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18; or a functional fragment thereof.

54. The method as claimed in claim 52, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

55. The method as claimed in claim 53, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

56. Use of a therapeutically effective amount of the conjugate of claim 1 for reducing tumor growth in a patient.

57. The use as claimed in claim 56, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

58. The use as claimed in claim 56, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

59. The use as claimed in claim 56, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

60. Use of a therapeutically effective amount of the fusion cDNA of claim 5 with a gene delivery technique for reducing tumor growth in a patient.

61. The use as claimed in claim 60, wherein said gene delivery technique is selected from the group consisting of: recombinant viral based vectors and plasmid DNA delivery methods.

62. The use as claimed in claim 60, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

63. The use as claimed in claim 60, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.
64. The use as claimed in claim 60, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.
65. Use of a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of claim 5 for reducing tumor growth in a patient.
66. The use as claimed in claim 65, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.
67. The use as claimed in claim 65, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.
68. The use as claimed in claim 65, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2,

IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

69. Use of a therapeutically effective amount of the conjugate of claim 1 for inhibiting a viral infection in a patient.

70. The use as claimed in claim 69, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

71. The use as claimed in claim 69, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

72. The use as claimed in claim 69, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

73. The use as claimed in claim 69, wherein said virus is selected from the group consisting of: Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

74. Use of a therapeutically effective amount of the fusion cDNA of claim 6 with a gene delivery technique to inhibit a viral infection in a patient.

75. The use as claimed in claim 74, wherein said gene delivery technique is selected from the group consisting of: recombinant viral based vectors and plasmid DNA delivery methods.

76. The use as claimed in claim 75, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

77. The use as claimed in claim 76, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

78. The use as claimed in claim 76, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

79. The use as claimed in claim 76, wherein said virus is selected from the group consisting of: Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

80. Use of a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of claim 5 to inhibit a viral infection in a patient.

81. The use as claimed in claim 80, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-

7; IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

82. The use as claimed in claim 80, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

83. The use as claimed in claim 80, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

84. The use as claimed in claim 80, wherein said viral infection is selected from the group consisting of : Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

85. Use of species-specific fusion cDNA of claim 5 with the cDNA of antigen or functional fragment thereof to allow production of antigen-specific antibodies in mammals.

86. The use as claimed in claim 85, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

87. The use as claimed in claim 85, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12,

CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

88. The use as claimed in claim 85, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

89. Use of a therapeutically effective amount of the conjugate of claim 1 to improve immune response in a patient.

90. The use as claimed in claim 89, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- α , Angiostatin, Endostatin, VEGF, TGF- β , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

91. The use as claimed in claim 89, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

92. The use as claimed in claim 89, wherein said interferons is selected from the group consisting of: IFN- α , IFN- β , IFN- γ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

1/18




FIG. 1

2/18




FIG. 2




FIG. 3

3/18




FIG. 4




FIG. 5

4/18




FIG. 6






FIG. 7


5/18

FIG. 5

6/18

FIG. 9


Model 377		17-J5330	Signal G:98 A:185 T:99 C:140	Page 1 of 2
Version 3.3	J53primer1		DT {BD Set Any-Primer}	Fri, May 19, 2000 2:18 AM
LR-377	J5330		207BD	Thu, May 18, 2000 5:08 PM
Version 3.3.1b2	lane 17		Points 1276 to 10624 Pk 1 Loc:1276	Spacing: 11.09(11.09)



77A	77A
-----	-----

8/18


Model 377 17-J5330 Signal G:98 A:185 T:99 C:140 Page 1 of 2
 Version 3.3 J53primer1 DT {BD Set Any-Primer} Fri, May 19, 2000 2:18 AM
 ABI IR-377 J5330 207BD Thu, May 18, 2000 5:08 PM
 PRISM Version 3.3.1b2 lane 17 Points 1276 to 10624 Pk 1 Loc:1276 Spacing: 11.09{11.09}



FEI-10A (Cont.)


9/18

Model 377 03-J53-30 Signal G:146 A:239 T:182 C:211 Page 1 of 2
 Version 3.3 J53 primer 2 DT (BD Set Any-Primer) Wed, May 24, 2000 9:23 AM
 LR-377 J53-30 207BD Tue, May 23, 2000 5:17 PM
 PRISM Version 3.3.1b2 Points 1129 to 10620 Pk 1 Loc: 1129 Spacing: 10.75(10.75)




10/18

Model 377 03-J53-30 Signal G:146 A:239 T:182 C:211 Page 1 of 2
 Version 3.3 J53 primer 2 DT (BD Set Any-Primer) Wed, May 24, 2000 9:23 AM
 ABI LR-377 J53-30 207BD Tue, May 23, 2000 5:17 PM
 PRISM Version 3.3.1b2 lane 3 Points 1129 to 10620 Pk 1 Loc: 1129 Spacing: 10.75(10.75)





FEI-10B (Cont.)



11/18

FIG-10C

12/18

FIG. 11FIG. 12

13/18





FIG. 13

14/18

FIG. 14

15/18





Fig. 15


16/18

FIG. 1B

17/18

2x

FIG-17B




40x

FIG-17D

2x

FIG-17A




40x

FIG-17C



SUBSTITUTE SHEET (RULE 26)

18/18

FIG. 18

SEQUENCE LISTING

<110> Galipeau, Jacques

Stagg, John

Centre for translational research in cancer

<120> A novel synthetic chimeric fusion

transgene with immuno-therapeutic uses

<130> 14226-10 PCT FC/VC

<150> US 60/330,476

<151> 2001-10-23

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> sequencing primer

<400> 1

acagccagct actaccagac

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> sequencing primer

<400> 2

cgctaccgga ctcagatctc

20

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035105 A3

(51) International Patent Classification⁷: C07K 14/535,
14/55, C12N 15/62, A61P 35/00

(21) International Application Number: PCT/CA02/01649

(22) International Filing Date: 23 October 2002 (23.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/330,476 23 October 2001 (23.10.2001) US

(71) Applicant (for all designated States except US): CENTRE
FOR TRANSLATIONAL RESEARCH IN CANCER
[CA/CA]; 3755 chemin de la Côte Ste-Catherine, Montréal,
Québec H3T 1E2 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GALIPEAU,
Jacques [CA/CA]; 251, Morrison, Town of Mount-Royal,
Québec H3R 1K7 (CA). STAGG, John [CA/CA]; 5245
Côte Ste-Catherine, Apt. 14, Montréal, Québec H3W 1M9
(CA).

(74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill
College Avenue, Montreal, Québec H3A 2Y3 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
18 September 2003

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 03/035105 A3

(54) Title: A SYNTHETIC CHIMERIC FUSION PROTEIN WITH IMMUNO-THERAPEUTIC USES

(57) Abstract: The present invention relates to an immuno-therapy conjugate which comprises A-c-B wherein: A and B are dif-
ferent and are compound ds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a
functional fragment thereof; and c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues. The
present invention also relates to a vaccine adjuvant comprising the immuno-therapy conjugate of the present invention. The present
invention further relates to a method of reducing tumor growth, for inhibiting a viral infection and for improving immune response
in a patient.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 02/01649

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/535 C07K14/55 C12N15/62 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, MEDLINE, BIOSIS, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 359 035 A (HABERMANN PAUL) 25 October 1994 (1994-10-25) the whole document -/-	1,2,5,6, 9-20, 23-25, 28,29, 32,33, 36-39, 42-44, 47-49, 52,53, 56,57, 60-62, 65,66, 69,70, 73-76, 79-81, 84-86, 89,90

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

3 July 2003

Date of mailing of the international search report

24/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Renggli, J

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 02/01649

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>SANG GOO LEE ET AL: "EFFECT OF GM-CSF AND IL-2 CO-EXPRESSION ON THE ANTI-TUMOR IMMUNE RESPONSE" ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 20, no. 4, July 2000 (2000-07), pages 2681-2686, XP009003638 ISSN: 0250-7005</p> <p>the whole document</p>	<p>1,2,5,6, 9-20, 23-25, 28,29, 32,33, 36-39, 42-44, 47-49, 52,53, 56,57, 60-62, 65,66, 69,70, 73-76, 79-81, 84-86, 89,90</p>
Y	<p>TSENG SHENG-HONG ET AL: "Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain." CANCER GENE THERAPY, vol. 6, no. 4, July 1999 (1999-07), pages 302-312, XP002246331 ISSN: 0929-1903</p> <p>abstract</p> <p>--- -/--</p>	<p>1,2,5,6, 9-20, 23-25, 28,29, 32,33, 36-39, 42-44, 47-49, 52,53, 56,57, 60-62, 65,66, 69,70, 73-76, 79-81, 84-86, 89,90</p>

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 02/01649

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	VILE R G ET AL: "CANCER GENE THERAPY: HARD LESSONS AND NEW COURSES" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, no. 1, January 2000 (2000-01), pages 2-8, XP008010621 ISSN: 0969-7128 page 3 -page 6	1,2,5,6, 9-20, 23-25, 28,29, 32,33, 36-39, 42-44, 47-49, 52,53, 56,57, 60-62, 65,66, 69,70, 73-76, 79-81, 84-86, 89,90
Y	GIOVANNI DE C ET AL: "The prospects for cancer gene therapy" INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD, NY, US, vol. 22, no. 12, December 2000 (2000-12), pages 1025-1032, XP002218907 ISSN: 0192-0561 abstract	1,2,5,6, 9-20, 23-25, 28,29, 32,33, 36-39, 42-44, 47-49, 52,53, 56,57, 60-62, 65,66, 69,70, 73-76, 79-81, 84-86, 89,90

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 02/01649

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MAECKER H T ET AL: "DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 15, no. 15, 1 October 1997 (1997-10-01), pages 1687-1696, XP004091940 ISSN: 0264-410X</p> <p>the whole document -----</p>	<p>1,2,5,6, 9-20, 23-25, 28,29, 32,33, 36-39, 42-44, 47-49, 52,53, 56,57, 60-62, 65,66, 69,70, 73-76, 79-81, 84-86, 89,90</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 02/01649

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: see reasoning
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 19, 20, 23-25, 28, 29, 32, 33, 36-39, 42-44, 47-49, 52, 53, 56, 57, 60-62, 65, 66, 69, 70, 73-76, 79-81, 84-86, 89, 90 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: see reasoning

Present claims 1-92 relate to an extremely large number of possible conjugates and uses/methods thereof. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found; however, for only a very small proportion of said conjugates claimed, namely for a SINGLE fusion protein comprising interleukin-2 and GM-CSF.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to conjugates comprising interleukin-2 and GM-CSF.

Claims 3, 4, 7, 8, 21, 22, 26, 27, 30, 31, 34, 35, 40, 41, 45, 46, 50, 51, 54, 55, 58, 59, 63, 64, 67, 68, 71, 72, 77, 78, 82, 83, 87, 88, 91 and 92 have consequently NOT been searched.

The remaining claims have been only partly searched, insofar as they relate to a conjugate comprising IL2 and GM-CSF.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

tion on patent family members

International Application No

PCT/CA 02/01649

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5359035	A	25-10-1994	
		DE 3545568 A1	16-07-1987
		DE 3712985 A1	03-11-1988
		AT 71144 T	15-01-1992
		AU 637139 B2	20-05-1993
		AU 6268390 A	13-12-1990
		AU 601959 B2	27-09-1990
		AU 6675686 A	25-06-1987
		CA 1341197 C	06-03-2001
		DE 3683267 D1	13-02-1992
		DK 619086 A	22-06-1987
		EP 0228018 A2	08-07-1987
		ES 2055686 T3	01-09-1994
		FI 865186 A ,B,	22-06-1987
		GR 3003999 T3	16-03-1993
		HU 44615 A2	28-03-1988
		IE 59779 B1	06-04-1994
		IL 81020 A	27-11-1995
		JP 2575367 B2	22-01-1997
		JP 62164695 A	21-07-1987
		KR 9405585 B1	21-06-1994
		NO 865191 A ,B,	22-06-1987
		PT 83972 A ,B	01-01-1987
		US 5298603 A	29-03-1994
		ZA 8609557 A	28-10-1987
		AT 79135 T	15-08-1992
		AU 613022 B2	25-07-1991
		AU 1466188 A	20-10-1988
		CA 1322157 C	14-09-1993
		DE 3873397 D1	10-09-1992
		DK 209188 A	17-10-1988
		EP 0288809 A1	02-11-1988
		ES 2033981 T3	01-04-1993
		FI 881743 A ,B,	17-10-1988
		GR 3006141 T3	21-06-1993
		HU 47319 A2	28-02-1989
		IE 61574 B1	16-11-1994
		IL 86086 A	24-01-1995
		JP 2667193 B2	27-10-1997
		JP 63301898 A	08-12-1988
		KR 9700187 B1	06-01-1997
		NO 881658 A ,B,	17-10-1988
		NZ 224247 A	26-04-1990
		PH 25327 A	30-04-1991
		PT 87237 A ,B	01-05-1988
		ZA 8802659 A	14-10-1988

Form PCT/SA/210 (patent family annex) (July 1992)